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Introduction to myasthenia gravis
Myasthenia gravis (MG) is one of the best characterised neuromuscular or autoimmune 
disorders. The Greek words myos (muscle) and asthenos (weakness) refer to the presence of 
pure motor weakness that can affect extraocular, bulbar, axial and limb muscles. Myasthenic 
weakness is characterised by its fluctuating nature and fatigability. When symptoms are 
restricted to ophthalmoparesis and ptosis, MG is classified as ocular MG (OMG). Weakness 
in other muscles is termed generalised MG (GMG). Thomas Willis was probably the first to 
describe a myasthenic patient in his book “De Anima Brutorum” from 1672. He described a 
“prudent and honest woman” suffering from fluctuating weakness in the arms and legs, but 
also from compromised articulation. 1 
“For some time she can speak freely and readily enough, but after long, hasty or 
laborious speaking she is not able to speak a word, but becomes mute as a fish and 
does not recover till after an hour or two”
It cannot be proven, nor ruled out, that this was in fact the first patient described with 
autoantibodies to muscle-specific kinase (MuSK), one of the key elements in neuromuscular 
signal transmission, as will be highlighted in this thesis. By the end of the 19th century, 
Wilhelm Erb and Samuel Goldflam provided a detailed description of the disease in which 
ptosis and ophthalmoparesis frequently occur as first symptoms, followed by weakness of 
chewing, swallowing and speaking, with a further spread towards neck and limb muscles. 
The clinical hallmark of MG is the fluctuating character of the weakness, becoming worse 
upon sustained movement and by the end of the day. 2,3 In 1934, Mary Walker reported a 
temporary improvement of facial weakness in an MG patient after subcutaneous injections 
of physostigmine. By then, it was known that physostigmine inhibited the breakdown of 
the neurotransmitter acetylcholine (ACh). Together with the discovery of the role of ACh in 
neuromuscular signal transmission by Dale and Feldberg in that same year, the pathology 
of MG was thought to be a curare-like poisoning of the “motor end-organs or myoneural 
junctions”. 4,5 The first description of histological malformation of the neuromuscular 
junction (NMJ) in MG patients was made by Coërs and Desmedt in 1959. 6 In 1960, after 
having studied 440 MG cases, the Scottish neurologist Simpson postulated the still current 
autoimmune hypothesis of the mechanism of MG, based on observations including thymic 
hyperplasia and occasional transfer of the disease from a mother to her newborn child during 
the first weeks of life. He also acknowledged a genetic susceptibility for immunological 
disorders such as systemic lupus erythematosus in patients and thyroid disease in their 
relatives. 7 In 1976, the biochemist Lindstrom induced antibodies as a coincidental side-effect 










































from electric eels. 8 The anti-AChR antibody positive and weak rabbits were recognised as 
being “myasthenic”. The final step was made when Lindstrom et al. were able to identify 
autoantibodies to the AChR as the causative factor for this transmission defect in 87% of 71 
MG patients. 9
Pathogenesis of classical MG with autoantibodies to aChr
The AChR is a cation channel formed by five subunits. In human muscle, two subtypes 
occur i.e. a fetal receptor consisting of two α1 subunits and one β1, γ and δ subunit, and an 
adult receptor in which the γ subunit is replaced by an ε subunit. The receptors are densely 
concentrated and located at the crests of the folds of the postsynaptic muscle membrane. 
A nerve action potential causes ACh to be released from presynaptic vesicles, which then 
diffuses across the synaptic cleft. Binding of ACh to the AChR depolarizes the postsynaptic 
endplate membrane generating an endplate potential which then opens Na+ channels located 
in the depths of the postsynaptic folds. This causes further depolarisation, finally triggering 
an action potential that propagates along the muscle fiber leading to muscle contraction. ACh 
diffuses out of the synaptic cleft or is readily hydrolysed by acetylcholinesterase (AChE) thus 
ending the depolarisation. The endplate potential generated by ACh release and binding of 
ACh to the AChR is normally much higher than the threshold needed to generate a muscle 
action potential. In myasthenic syndromes this safety factor is typically compromised, either 
by pre- or postsynaptic pathology. 
In classical MG with autoantibodies to the AChR (AChR MG), the antibodies affect the 
neuromuscular transmission in three ways. Firstly, antibodies can directly compete with ACh 
binding, although titres of such blocking antibodies only weakly correlated with disease 
severity. 10 More importantly, antibodies are able to crosslink AChRs, thereby increasing 
AChR turnover through internalisation and lysosomal degradation by muscle fibers. 11 
However, the third and most crucial factor affecting transmission is a reduction in the number 
of available AChRs and changes in endplate morphology due to complement activation, 
as was shown by Lennon et al. in a rat model using passive and active immunisation. 12 
Complement deposition was located at the neuromuscular junction in MG patients 
correlating with destruction of the folded postsynaptic membrane. 13,14 In 1987, Rodgaard et 
al. published the predominance of antigen-specific IgG subclasses 1 and 3 directed to AChR 
in MG patients. Those subclasses are well known for their complement activating capacity. 15 
The presence of other autoimmune diseases in patients with AChR MG and their first-degree 
relatives suggests a role for a genetic predisposition. The human leukocyte antigen (HLA) 
concerns large number of genes that encode proteins involved in the presentation of antigens 










































the human population is an important factor determining the flexibility of the acquired 
immune system. However, several HLA haplotypes are thought to increase the likelihood of 
developing autoimmune diseases. For example, the HLA A1-B8-DR3 ancestral haplotype is 
associated with many autoimmune diseases, including Graves’ disease, 16 celiac disease, 17 the 
Lambert-Eaton myasthenic syndrome (LEMS) without small cell lung carcinoma, 18 and type 
I diabetes mellitus. 19 AChR MG without thymoma and an onset before the age of 40 years 
is also strongly associated with this haplotype in white Europeans. 20-23 By contrast, late onset 
MG which occurs more frequently in men has been linked to HLA DR2. 23-25
Definition of “seronegative” MG
The discovery of antibodies to the AChR in the majority of MG patients in 1976 immediately 
defined a group of patients diagnosed as MG based on their phenotype in whom no such 
antibodies could be found. They were defined as “seronegative” MG (SNMG). Between 1976 
and 1990, the prevalence of SNMG was reported in at least 12 studies. Overall SNMG was 
present in 48.1% of patients who had ocular symptoms only (weighted average of n = 412, 
range 21-83%) and 11.5% of patients with generalised weakness (weighted average of n = 
2272, range 6-25%). 9,23,26-35 Although the lower frequency in GMG compared to OMG is 
consistently found, the large variability probably reflects patient selection and referral bias.
Multiple explanations for the absence of antibodies in the presence of a myasthenic phenotype 
were proposed including the possibility of seroconversion early in the course of the disease, 
36 seroconversion after treatment with immunosuppressive therapy, 29,36,37 or during periods 
of clinical remission. 38 In children, seroconversion has been described occurring after many 
years, ranging from 5-10 years, after the onset of (ocular) symptoms. 39
Adaptations to the assays used to detect AChR antibodies decreased the number of SNMG 
patients by using human AChR instead of rat or calf derived AChR, 40,41 a mixture of human 
AChR derived from normal and denervated muscle instead of denervated muscle only, 42 
or AChR derived from cell lines. 43 This fine-tuning has continued in recent years through 
the introduction of cell-based assays using sensitive fluorescence techniques to detect low-
affinity antibodies as will be highlighted in the Chapters 3 and 5 of this thesis. 44
Finally, it became clear that congenital myasthenic syndromes caused by mutations in 
proteins involved in neuromuscular transmission such as rapsyn and Dok7 could also present 
as a late onset phenotype. 45,46
However, strong evidence arose that SNMG was in fact an acquired autoimmune disease 
caused by autoantibodies directed to unknown antigens. Firstly, clinical symptoms responded 
to immunosuppressive therapy and plasmapheresis. 27,34,47,48 Secondly, the disease could be 










































human serum or IgG from SNMG patients caused a neuromuscular transmission defect and 
possibly a small loss of AChRs in the mouse diaphragm. 51,52 Moreover, IgG from SNMG 
patients was shown to bind to an unknown antigen present on a muscle cell line. 53
autoantibodies to Musk in seronegative myasthenia gravis
In 2001, Hoch et al. were the first to describe autoantibodies in 17 out of 24 patients with 
generalised SNMG directed to the extracellular domain of an antigen called muscle-specific 
kinase (MuSK) using immunofluorescence on transfected cells, immunoprecipitation and 
ELISA. The autoantibodies also interfered with MuSK function, i.e. they prevented the 
formation of AChR clusters normally induced by nerve-derived agrin. 54 Patients with MG 
who had autoantibodies to MuSK (MuSK MG) appeared to differ clinically from AChR 
antibody negative/MuSK antibody negative patients because weakness was more prominent 
in oculobulbar muscles with frequent respiratory insufficiency. 55 In the MuSK MG group, 
treatment with oral immunosuppressants seemed less effective. Some MuSK MG patients 
adversely responded to AChE inhibitors with widespread fasciculations, and muscle atrophy 
occurred later in the course of the disease. 56 In retrospect, this phenotype had already been 
identified as a subgroup within a cohort of SNMG patients by Evoli et al. in 1996. 57 Studying 
larger cohorts of AChR Ab- MG patients, the percentage of MuSK MG was adjusted 
downward leaving a significant group of AChR Ab-/MuSK Ab- patients nonetheless.
The role of Musk in the neuromuscular junction
Synaptic development of a neuromuscular junction requires specialisation of muscle 
fibers in the proximity of a motor nerve terminal. This specialisation includes at least two 
mechanisms, i.e. the local transcription of specific proteins by the synaptic nuclei including 
the AChR subunits, and the redistribution of pre-existent molecules present on the surface of 
the myofiber. The result is clustering of AChRs on the crests of the postsynaptic membrane 
folds and the formation of postsynaptic intracellular signalling pathways. 
Nerve-derived agrin, a 200 kDa heparin sulphate glycoprotein, proved able to aggregate 
AChR in cultured chicken myotubes, a process inhibited by polyclonal anti-agrin antibodies. 
58 Because phosphotyrosine staining in myofibers is concentrated at the NMJ and tyrosine 
kinases are often involved in cell-cell interaction, Jennings et al. used polymerase chain 
reaction (PCR) to look for tyrosine kinases in the electric organ and skeletal muscle of the 
electric ray Torpedo californica. They were able to isolate a transmembrane tyrosine kinase with 










































cDNA from rat muscle and both normal and denervated human muscles. They introduced 
the term muscle-specific kinase (MuSK). In this study, MuSK colocalised with AChR at the 
neuromuscular junction. MuSK expression was upregulated after fusion of myoblasts to form 
myotubes. In normal adult muscle, MuSK was present only at the neuromuscular junction, 
but MuSK and AChR transcripts became widely detectable throughout the myofibers after 
denervation. Activated MuSK dimerizes and triggers phosphorylation of the β subunit of 
the AChR. 60
The MuSK gene contains 14 exons and maps to chromosome 9q in humans and to chromosome 
4 in mice. 61 The extracellular domain of MuSK contains 4 immunoglobulin-like domains 
and a cystein rich domain. MuSK has a molecular weight of 110 kDa and contains a single 
transmembrane region followed intracellularly by a juxtamembrane domain containing one 
of the four tyrosine residues (Tyr553) that is first autophosphorylated upon activation by 
agrin (Figure 1.1). 62 Next is the catalytic domain containing the tyrosine kinase itself. This 
kinase contains three tyrosine autophosphorylation sites in an activation loop (Tyr750, 754 
and 755). Such a loop is a general characteristic of the receptor tyrosine kinase family that 
autoregulates catalytic activity by obstructing adenosine triphosphate (ATP) and substrate 
binding. After phosphorylation of the tyrosine residues, MuSK is switched to a stable active 
state. 63 Activated MuSK is then rapidly internalised through endocytosis which is also a 
common property for receptor tyrosine kinases. 64
Interactions with other proteins
Agrin
In 1996, DeChiara et al. reported on a mouse model carrying a MuSK gene disruption in 
which mice were immobile and died at birth. Their skeletal muscles were grossly normal, 
indicating normal early skeletal muscle development. However, pre- and postsynaptic 
differentiation was absent, and intramuscular nerves were not able to contact the muscle 
fibers. 65 Postpartum inhibition of MuSK by RNA interference also induced the disassembly 
of NMJs that had already been built, indicating also a role for MuSK in NMJ maintenance. 
66 Mice lacking agrin showed a remarkably similar phenotype either dying in utero or being 
stillborn. 67 In 1996, Glass et al. reported that agrin was indeed the factor inducing the 
phosphorylation of MuSK. Even long-lasting phosphorylation of MuSK and AChR, as well 
as clustering, can be initiated be a single five minute pulse of agrin. 68 In 2006, Stiegler et 











































No direct binding of agrin to the MuSK ectodomain could be demonstrated. Phosphorylation 
of MuSK in response to agrin only took place in myotubes, but not in myoblasts or other 
cell types, transfected with a MuSK expression factor. This suggested the presence of 
another hypothetical component termed myotube associated specificity component (MASC). 
70 Moreover, whereas the intracellular MuSK kinase domain was sufficient for MuSK 
autophosphorylation and AChR phosphorylation, the ectodomain of MuSK was essential for 
clustering of the AChRs. 71 In 2006, Weatherbee et al. showed that mice with a mutation 
in the gene encoding the low-density lipoprotein receptor-related protein 4 (LRP4) died 
at birth and their synapses had both pre- and postsynaptic defects very much like MuSK 
mutant mice. This included aberrant motor axon growth, axonal branching and a lack of 
postsynaptic clustering. 72 In 2008, the receptor for neural agrin proved to be LRP4 according 
to two independent groups. 73,74 LRP4 associates with itself and forms a complex with MuSK 
in the absence of agrin. LRP4 is expressed specifically in myotubes, but not myoblasts, 
thereby explaining its function as the above mentioned MASC. The intracellular domain of 
MuSK becomes tyrosine phosphorylated upon stimulation of LRP4 with agrin. The binding 
between LRP4 and agrin is enhanced approximately 20 fold by the presence of calcium. 73
Rapsyn
Similar to MuSK, the intracytoplasmatic protein rapsyn (an acronym for receptor-associated 
protein of the synapse) was also known to colocalise with AChR at the developing NMJ. In 
1995, Gautam et al. showed that rapsyn null mice died within hours after birth. There were 
no detectable AChR clusters anywhere along the muscle fibers which proved that rapsyn 
was essential for clustering. 75 Recently, the binding between AChR and rapsyn was found 
to depend on a 20 amino acid motif in the intracellular domain of the AChR β subunit in 
which one tyrosine amino acid (Tyr390) is phosphorylated through the agrin-MuSK pathway. 
Because rapsyn has also AChR binding capacity independent of the β loop, it is postulated 
that more than one rapsyn molecule can bind to phosphorylated AChR. Rapsyn thus acts as 
a scaffold protein in the NMJ. 76
Dok7
The cytoplasmatic protein Dok7 (downstream of tyrosine kinase 7) also proved essential for 
NMJ formation. Okada et al. showed that Dok7 null mice died at birth and did not form 
AChR clusters or NMJs. 77 
The phosphorylated tyrosine in the juxtamembrane domain of MuSK mentioned earlier 
(Tyr553) becomes a docking site for the phosphotyrosine binding site of Dok7. A tetramer 
is then created in which a Dok7 dimer binds to two MuSK monomers (Figure 1.1). The 










































MuSK activation loop. Therefore Dok7 is not only a substrate for MuSK, but also activates 
the catalytic domain. 78 The binding of Dok7 to MuSK is also dependent on the interaction 
of MuSK and a tumorous imaginal disc protein (Tid1), which function remains to be clarified 
further. 79
Acetylcholinesterase (AChE)
An important enzyme in limiting the duration of the presynaptic trigger by the released 
ACh is acetylcholinesterase (AChE). This enzyme is organised into 3 tetramers of catalytic 
subunits that are linked to collagen Q (ColQ), a triple helical collagen subunit. ColQ itself 
is connected to the postsynaptic basal lamina by binding to perlecan, but also to MuSK 
through its C-terminal domain. 80
Intracellular interactions
The intracellular pathways leading from MuSK activation to a fully developed NMJ with 
stable AChR clusters and a sustained MuSK activation are becoming increasingly complex 
and remain poorly understood. It requires the presences of multiple intracytoplasmatic 
enzymes like geranylgeranyltransferase I and Rac I essential for the first micro aggregates, 
Rho GTPase and possibly PAK1 that are involved in the formation of larger clusters and 
non-receptor tyrosine kinases like Src and Abl that play a role in the early and late response 
to agrin. Multiple enzymes have been found to contribute to negative feedback pathways and 
are involved in the disassembly of AChR clusters. As mentioned earlier, activated MuSK is 
internalised through endocytosis. For this process, the ATPase N-ethylmaleimide sensitive 
fusion protein (NSF) that binds directly to MuSK is essential. 64 Internalised MuSK is 
probably degraded upon binding to the ubiquitin tag to direct it to the proteasome. In this 
respect, a PDZ domain containing RING finger 3 (PDZRN3) ligase has been identified that 
binds to MuSK and regulates MuSK cell surface levels. 81 MuSK also binds to caveolin 3, 
a structural protein component of caveolae in muscle cells, but the role of this interaction 
remains to be elucidated. 82 A delicate balance between these mechanisms probably guides 
the ongoing process of building and remodelling of NMJs. 83 
role of Musk prior to neural innervation
AChR clusters are also formed on immature muscle fibers prior to the innervation by motor 
nerves. In 2001, Lin et al. showed that in mice during embryogenesis at day 14.5 AChR 
clusters were present, but not apposed by a nerve terminal whereas at day 18.5 all remaining 
clusters were apposed by a nerve terminal. This process, called prepatterning, is restricted to 
the central part of the muscle fiber. However, no clustering took place in MuSK or rapsyn 
mutant models indicating that these two proteins are also essential in clustering prior to 
neural innervation. Agrin was found to be essential in a later stage for stabilisation and 










































Yang et al. reported similar results in a mouse model in which motor neurons lose their ability 
to differentiate through inactivation of the homeodomain transcription factor HB9. AChRs 
still cluster in these mice, and AChR transcription is increased in the central region of the 
diaphragm muscle, although in a wider zone than normal. For this clustering, postsynaptic 
MuSK, but not nerve-derived agrin, proved to be essential. 85 In 2008, Kim and Burden 
showed that MuSK expression itself is patterned in this central region of the muscle fiber 
in the absence of neural innervation, and that ectopic MuSK expression induces ectopic 
AChR clusters promoting axonal outgrowth. 86 Recently, a key protein in this pre-patterning 
process of developing muscle fibers proved to be the dihydropyridine receptor (DHPR), the 
L-type calcium channel in muscle. 87 This transmembrane protein acts as a voltage sensor. 
On depolarization of the sarcolemma, it activates the associated type 1 ryanodine receptor, 
leading to a release of calcium from the sarcoplasmatic reticulum, which then triggers 
muscle contraction. Chen et al. showed that in knockout mice lacking the β1 subunit of 
the L-type calcium channel DHPR (Cacnb1-/-), but also in double knockout mice lacking 
Cacnb1 and HB9, the pre-patterning of AChR clusters was lost. Nonetheless, synapses were 
established, but myofibers from DHPR deficient mice contained multiple endplates whereas 
the majority of control myofibers contained only a single endplate.
In summary, MuSK is involved in calcium-dependent aneural prepatterning of AChR 
clusters and in neural AChR cluster formation in the mature endplate. It is not clear if 
these aneural clusters are essential for NMJ formation, but they may serve as target for 
motor axons toward the centre of the muscle fiber. Neural agrin then binds through LRP4 
to MuSK, causing autophosphorylation of the juxtamembrane domain and the active loop 
of the kinase. MuSK is thus switched to an active state which is enhanced by the binding 
of Dok7, creating a tetramer of two MuSK monomers and one Dok7 dimer. The β subunit 
of AChR is phosphorylated, enhancing its binding to the rapsyn scaffold protein. Activated 
MuSK is internalised and its active state is maintained by intracellular kinases, stabilising 
the NMJ independently of the presence of agrin. The essential role of most of these proteins 
in human neuromuscular transmission is further substantiated by the description of several 










































Figure 1.1 The assembled dimeric Musk signalling complex 
The extracellular domain contains 4 immunoglobulin-like domains and a cystein rich domain and interacts with 
the agrin binding receptor LRP4. Reprinted from the International Journal of Biochemistry and Cell Biology, 
Volume 43, Ghazanfari et al., Muscle specific kinase: organiser of synaptic membrane domains, Page 296, 










































aims of the thesis
The aim of the studies in this thesis was to investigate the pathogenesis and the underlying 
immunological defect of MuSK MG. To reach this goal a detailed characterisation of the 
clinical course and features of patients with MuSK MG, and a study of the antibody response 
to the MuSK protein were first performed.
The discovery of anti-MuSK antibodies in a subset of patients classified until then as having 
“seronegative” MG (SNMG) raised the question whether these autoantibodies defined a new 
and distinct clinical disorder different from AChR MG. To investigate this, we first studied 
the epidemiology of MG subtypes in the Netherlands on a regional level using a well-defined 
area in the province of Zuid-Holland with a long-lasting and complete MG registry (Chapter 
2). This enabled us to calculate population based data on the prevalence and incidence of the 
different subtypes of generalised MG. 
We then undertook a nationwide study of patients with acquired generalised MG in the 
absence of AChR antibodies. This led to the identification of a relatively large cohort of 
SNMG and MuSK MG patients. Next, we described the clinical characteristics of MuSK 
MG patients and compared them to a cohort of AChR MG patients matched for sex and age 
at onset, and to patients with SNMG (Chapter 3). The immunopathological mechanism of 
MuSK MG was studied in more detail by investigating the association between MuSK MG 
and HLA haplotypes, described in Chapter 4. Longitudinal MuSK MG sera were collected 
to correlate antigen-specific IgG subclasses to clinical disease severity, thus substantiating 
their role in the immunopathogenesis (Chapter 5). In addition we searched for new antigens 
in AChR Ab-/MuSK Ab- patients. We hypothesised the existence of antibodies to the 
postsynaptic ErbB receptor, because ErbB is also a transmembrane protein accessible to an 
immunoresponse and involved in the development of the NMJ (Chapter 6).
Two case studies highlight the pivotal immunological role of IgG4 autoantibodies to MuSK 
(Chapter 7) and the electrophysiological characteristics of the neuromuscular transmission 
defect in MuSK MG (Chapter 8). Finally, overall results are summarised and discussed 
(Chapter 9).
II
Epidemiology of myasthenia gravis with 
anti-muscle-specific kinase antibodies in 
the Netherlands
E.H. Niks 1, J.B.M. Kuks 2, J.J.G.M. Verschuuren 1
1 Department of Neurology, Leiden University Medical Center, The Netherlands
2 Department of Neurology, University Medical Center Groningen, The Netherlands. 











































The epidemiology of myasthenia gravis subtypes and the frequency of antibodies against 
muscle-specific kinase (MuSK) were studied in patients with generalised myasthenia gravis 
without anti-acetylcholine receptor antibodies who had an onset of symptoms between 
1990 and 2004 in a well-defined region in the Netherlands. The nationwide prevalence and 
incidence myasthenia gravis with anti-MuSK antibodies were also studied. MuSK antibodies 
were found in 22% of patients with generalised myasthenia gravis without anti-acetylcholine 
receptor antibodies. Nationwide, 35 patients with MuSK myasthenia gravis were identified, 
yielding a prevalence of 1.9 per million (95% confidence interval (CI) 1.22 to 2.59) and an 








































Epidemiology of MuSK MG in the Netherlands
21
Introduction
In North American and European cohorts, 38-47% of patients with generalised myasthenia 
gravis without anti-acetylcholine receptor antibodies (AChR Ab- MG) have antibodies to 
muscle-specific kinase (MuSK). 56,92,93 By contrast, this proportion is only 4% in Taiwan, 
and myasthenia gravis with anti-muscle-specific antibodies (MuSK Ab+ MG) seems to be 
absent in Norway, suggesting large regional differences. 94,95 We studied the epidemiology of 
myasthenia gravis subtypes, the proportion of MuSK Ab+ MG in patients with generalised 
AChR Ab- MG in a well-defined region in the Netherlands, and the nationwide prevalence 
and incidence of MuSK Ab+ MG.
Methods
Patients 
Patients diagnosed with any form of myasthenia gravis in the densely populated northern part 
of the province of Zuid-Holland have been followed up by our centre since January 1 1990 
as described previously. 96 All patients with myasthenia gravis, with an onset of symptoms 
up to January 1 2004 while living in this region were included in the regional study. In 
addition, all eight university medical centres and five larger general hospitals included 
patients with generalised AChR Ab- MG in the nationwide study up to January 1 2006 by 
listing patients under current treatment, searching computerised diagnosis registrations, 
and the use of patients identified in an earlier study. 31 
Inclusion criteria for aChr ab- MG
The diagnosis was based on clinically confirmed fluctuating weakness of voluntary muscles 
acquired after the age of 2 years and the absence of anti-acetylcholine receptor (AChR) 
antibodies. Ocular myasthenia gravis was diagnosed when only diplopia or ptosis had been 
present throughout the course of the disease. The presence of mild weakness of lid closure 
was allowed for the diagnosis. Generalised myasthenia gravis was defined as the involvement 
of muscles other than external eye muscles, the levator palpebrae or the orbicularis oculi. 
The diagnosis was considered to be confirmed electrophysiologically if a decrement of the 
compound muscle action potential of more than 10% had been found during repetitive 













































The month in which the first MG symptoms had occurred was noted according to the patient’s 
chart. Patients with AChR Ab- MG were asked for informed consent by their attending 
neurologist. Serum was tested for the presence of anti-MuSK, anti-AChR and anti-voltage-
gated calcium channel antibodies using standardised immunoprecipitation assays (RSR Ltd., 
Pentwyn, Cardiff, UK) and patients were re-examined by EHN for confirmation of clinical 
criteria and the time of onset. Population figures were provided by Statistics Netherlands. 
statistics
Incidences were computed using the number of patients with the onset of symptoms between 
January 1 1990 and January 1 2004 and the total observed person-years. Prevalences were 




We identified 288 patients in whom myasthenia gravis had been considered. After reviewing 
their charts, 35 were excluded because of a revised diagnosis (n=30), congenital myasthenia 
gravis (n=2) or lack of sufficient data to confirm the diagnosis (n=3). Of the remaining 
253 patients with clinical myasthenia gravis, 189 tested AChR Ab+. On January 1 2004, 
160 patients were alive and 111 had an onset between 1990 and 2004. Information on the 
antibody status of eight patients was not available, leaving 56 patients with AChR Ab- MG. 
In this group, 30 had ocular myasthenia gravis (45% of all patients with ocular myasthenia 
gravis), in whom no anti-MuSK antibodies were found. In 26 patients with generalised 
AChR Ab- MG (14.5% of all patients with generalised myasthenia gravis), diagnosis had 
been confirmed electrophysiologically in 16 and by a positive response to acetylcholinesterase 
inhibitors in 8. In the other two patients the diagnosis had been based on clinical symptoms. 
Three patients died before the onset of the study. Among the remaining 23 patients, anti-
MuSK antibodies were present in 5 (22%, 3 women and 2 men). All five were alive on January 
1 2004 and four had an onset between 1990 and 2004. A flow chart of this classification of 



























































































Figure 2.1 regional patients classified according to MG subtypes










































During this period, the regional population increased from 1 641 227 to 1 778 564, yielding 
a total of 23 926 703.5 observed person-years. Table 2.1 shows the prevalences on January 1 
2004 and the average annual incidence of myasthenia gravis subtypes.










Regional MuSK Ab+ MG   2.8*  0.30 - 5.33 0.17* 0.00 - 0.33 
Nationwide MuSK Ab+ MG   1.9*  1.22 - 2.59 0.10* 0.06 - 0.14
AChR Ab+ MG 90.0  75.8 - 104.2 4.64 3.76 - 5.52
Generalised AChR Ab-/MuSK Ab- MG 10.1    5.3 - 14.9 0.38 0.13 - 0.63
AChR Ab+ MG, myasthenia gravis with anti-acetylcholine receptor antibodies; AChR Ab- MG, myasthenia 
gravis without acetylcholine receptor antibodies; MuSK Ab- MG, myasthenia gravis without anti-muscle-specific 
kinase antibodies. 
* Differences between regional and nationwide data are not statistically significant 
Nationwide patients
We identified 130 patients diagnosed with generalised AChR Ab- MG. After clinical re-
examination, 21 were excluded because of low anti-AChR titres in newly acquired serum 
(n=14) or not meeting clinical criteria (n=7). Anti-voltage-gated calcium channel antibodies 
were found in one patient. MuSK antibodies could not be determined in 11 patients because 
of a lack of informed consent (n=4), loss to follow-up (n=3) or death (n=4). Among the 
remaining 97 patients anti-MuSK antibodies were found in 35 (36%), of whom two died 
before the onset of the study. Thirty three patients were clinically re-examined. There was 
a female predominance (27 vs. 8). Median age at onset was 30.5 (range 2.0-74.6) years. 
We identified 30 white patients, two Creoles, one Persian, one Iraqi and one of Balkan 
origin. Median time from the onset of symptoms to a diagnosis of myasthenia gravis (not 
MuSK Ab+ MG), was 9 months (range 1 month-33 years). The neuromuscular transmission 
defect had been confirmed by EMG in 31 patients although no single-fiber EMG had been 
performed in the other four. Three of these four had shown a positive response to intravenous 
acetylcholinesterase inhibitors.
On January 1 2004, 31 patients were alive, and 22 had an onset between 1990 and 2004. The 
annual incidence fluctuated between 0 and 4 patients per year without a trend to increase. 
From January 1 1990 to January 1 2004, the population increased from 14 892 574 to 
16 258 032 inhabitants. Nationwide prevalence and incidence rate of MuSK Ab+ MG are 
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Discussion
MuSK Ab+ MG is found only in a minority of patients with generalised AChR Ab- MG 
in the Netherlands. The difference between the regional and non-regional proportion of 
MuSK Ab+ MG is not statistically significant (odds ratio 0.41, 95% CI 0.14 to 1.22). The 
lower regional proportion of 22% seems a more accurate estimate coming from a population 
based registration of all myasthenia gravis subtypes. Regional prevalence and incidence of 
AChR Ab+ MG are comparable to those found in other European countries, varying between 
77 and 105 per million and between 3.8 and 7.4 per million per year. 97 The proportions 
of AChR Ab- patients in the groups with ocular and generalised myasthenia gravis are 
comparable to historical data indicating that no large referral bias towards AChR Ab- MG 
occurred. Nationwide, not all patients with generalised AChR Ab-/MuSK Ab- MG who 
have often only mild generalised weakness, 56 may have been referred to one of the tertiary 
centres involved, increasing the proportion of patients with MuSK Ab+ MG. The higher 
proportion of 36% MuSK Ab+ MG nationwide is comparable to 38% in North American, 
41% in British and 47% in Italian cohorts, and selection or referral bias may well cause 
this variation. By contrast, the low prevalence of MuSK Ab+ MG in Taiwanese and Danish 
patients (F. Somnier, oral communication) and its absence in Norway also suggest a genetic 
or environmental susceptibility, which was previously proposed in other autoimmune 
diseases. T helper cell 1-mediated diseases such as type-1 diabetes and multiple sclerosis 
have increased prevalences at higher latitudes, whereas pemphigus vulgaris, thought to be 
T helper cell 2 mediated, has lower prevalences at higher latitudes. 98 MuSK Ab+ MG is 
comparable to pemphigus vulgaris with regard to a predominance of IgG4 in active disease 
and an association with the HLA-DR14-DQ5 haplotype. 93,99 Epidemiologic data from other 
countries may be helpful to confirm regional differences in the prevalence of MuSK Ab+ MG 
and to identify possible aetiological mechanisms.
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The diagnosis of seronegative myasthenia gravis (SNMG) depends on the absence of antibodies 
to known antigens in the neuromuscular junction, and therefore on the sensitivity of the 
assays that have been used. Differences in clinical course between MG subtypes have been 
described, but studies often lack a standardised approach or a direct comparison of groups. In 
this nationwide study, we compared MuSK MG patients to AChR MG controls matched for 
sex and age of onset and to SNMG patients. Symptoms were investigated using standardised 
history taking and cross-sectional examination and analysed with survival statistics. New 
serum was acquired and tested for antibodies using radioimmunoassays. Forty-one SNMG 
patients, 25 MuSK MG and 50 AChR MG controls were included. During the course of 
the study, cell-based assays became available to detect antibodies to AChR or MuSK using 
immunofluoresence in human embryonic kidney cells with expressed recombinant AChR 
subunits and rapsyn, or over-expression of recombinant MuSK. These assays identified 
10 patients with antibodies to overexpressed MuSK and another 10 with antibodies to 
clustered AChR. The phenotype of the remaining 21 SNMG patients was characterised by 
mild proximal limb-girdle weakness with prominent extraocular involvement. Apart from 
more proximal leg weakness in SNMG, symptoms in the first month did not discriminate 
between the subtypes. Analysing subsequent occurrence of symptoms, hazard ratios for 
dysarthria, dysphagia, neck weakness, and dyspnoea were significantly increased in MuSK 
MG compared to SNMG. Among bulbar symptoms in MuSK MG patients, chewing was 
relatively spared which seems consistent with MRI studies. The phenotype of MuSK MG 
patients identified by the cell-based assay was milder, but comparable, to that of the original 
MuSK MG cohort identified by radioimmunoassay. Cell-based assays are useful to define a 
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Introduction
Fluctuating weakness of voluntary muscles is the clinical hallmark of myasthenic syndromes. 
In acquired autoimmune myasthenia gravis (MG), weakness is caused by antibodies directed 
to antigens in the neuromuscular junction. The antigen most frequently involved is the 
postsynaptic acetylcholine receptor (AChR). Autoantibodies to muscle-specific kinase 
(MuSK) in patients with AChR antibody negative MG were first described in 2001. 54 
Recently, the low-density lipoprotein receptor-related protein 4 has been postulated as 
another antigen in AChR antibody negative MG, although some of these patients also have 
antibodies to MuSK and their pathogenicity remains to be proven. 100-102 A diagnosis of 
seronegative MG (SNMG) is based on clinical symptoms and depends by definition on the 
absence of antibodies and therefore on the sensitivity of the assays used to detect them. 
Ideally, the neuromuscular transmission defect should also be proven by electrophysiological 
studies. However, the sensitivity of these tests depends on the level of clinical involvement 
of the muscles under study. The tests are also technically challenging, often uncomfortable 
to patients, and therefore have not always been performed to the fullest extent. Antibodies 
to AChR or MuSK are demonstrated using radioimmunoassays (RIA). Modifications of the 
AChR assay first described in 1976 increased its sensitivity and limited the proportion of 
generalised SNMG patients. 42 In 2008, a cell-based assay was described using transfected 
AChR molecules clustered with rapsyn cotransfected in human embryonic kidney cells, 
defining a further 60% of SNMG patients as antibody positive. 43 In the present study, we 
introduce a similar approach to detect antibodies to MuSK in AChR antibody negative MG. 
MG is a whimsical disease with significant variation in the distribution and severity of 
weakness between patients and between different muscles of the same patient. MuSK MG 
seems clinically distinguishable from AChR MG and SNMG because of predominantly 
bulbar weakness, affecting speech, swallowing and facial muscles in most patients, 56,92,103-110 
although weakness of neck extensors can also be found. 92,105,107,111,112 Respiratory crises occur 
in approximately one quarter to one third of the patients. 56,92,104-107,110 Presenting symptoms 
are mainly ocular according to some. 56,108 However, an onset with (oculo)bulbar symptoms, 
weakness of neck extension, respiratory insufficiency or generalised weakness has also been 
reported. 92,104,111 After several years, the fluctuating character of the weakness seems to 
become less manifest in some of the patients, which is accompanied by atrophy of facial and 
tongue muscles. 56,103,104,107,110 Acetylcholinesterase inhibitors often do not improve weakness, 
56,105,109,111 and can even lead to muscular fasciculations. 56,110
SNMG emerges as a more heterogeneous disease. Weakness seems less severe in the majority of 
patients with predominant involvement of limb muscles and external eye muscles. However, 
bulbar, neck and respiratory muscles can be frequently affected as well. 56,105,111 Others claim 










































crises in nearly 20%. 106 Until now, none of the clinical studies applied a standardised 
protocol to assess the distribution of initial, presenting and most severe weakness or the 
course of symptoms in time. It is often not clear whether information is based on review of 
charts or standardised cross-sectional examination. The MGFA or Osserman’s classifications 
often used offer only a limited description of clinical symptoms. 1,113 Three studies made 
a direct comparison between MuSK MG and AChR MG, but patients were included 
consecutively without some form of matching. 106,112,114 Only few studies have presented 
both cross-sectional data and information on the longitudinal course of the disease. 56,104 In 
all clinical studies, the definition of SNMG was based on conventional RIA.
Detailed information on the course of symptoms may help in the early diagnosis of this 
rare disorder. Knowledge of clinical patterns of weakness and response to therapy is also 
important for individual patients and their physicians, and for the design of future clinical 
trials. The newly developed cell based techniques to test for antibodies to the AChR or 
MuSK enable application of more rigorous criteria for SNMG. To study the symptomatology 
of MuSK MG and SNMG in detail and to investigate whether they are clinically different 
from AChR MG, we compared the course of symptoms, rate of progression, distribution 




Patients with generalised MG without AChR antibodies were included from a nationwide 
study as described previously. 115 In brief, charts from 130 patients with a diagnosis of acquired 
MG without AChR antibodies were screened in all eight University Medical Centers and 
five large General Hospitals in the Netherlands. Twenty-one were excluded because of low 
anti-AChR titres in newly acquired serum (n=14) or not meeting clinical criteria (n=7). 
Voltage gated calcium channel antibodies were found in one patient. MuSK antibodies were 
present in 35 patients, but could not be determined in 11 patients, either because of a lack 
of informed consent (n=4), loss to follow-up (n=3) or death (n=4). This yielded a total of 62 
eligible SNMG patients. 
The clinical course of the disease from the first 25 consecutively included patients with 
MuSK MG was compared to that of 50 matched control patients with generalised non-
thymoma AChR MG. These controls were selected from our database containing a complete 
registration of all MG patients in the northern part of the province of Zuid-Holland since 
1990. MuSK MG patients and controls were matched in a 1 to 2 ratio for sex and the 








































Clinical comparison of myasthenia gravis subtypes
31
SPSS 12.0.1 statistical software (SPSS Inc, Chicago, Illinois, USA). Patients were asked for 
informed consent by their attending physician. The medical ethical committees of all centres 
involved approved of the study.
All patients were re-examined by a single investigator (EHN) using a standardised history 
taking and physical examination. Using information from this history and the patients’ 
chart, the month was noted in which various symptoms had occurred for the first time. The 
symptoms and signs under investigation were diplopia, ptosis, impaired facial expression, 
articulation, swallowing, chewing, and tongue movements, weakness of the neck (flexion or 
extension), dyspnoea, invasive ventilatory support, and proximal and distal muscles in arms 
and legs. Patients were excluded from clinical analysis if they had insufficient recollection of 
the course of their disease during these first years and if letters and notes in their chart did 
not provide this information. Patients were also excluded who had coexisting diseases with 
symptoms not distinguishable from MG symptoms. 
Definition of MG subgroups
The diagnosis of SNMG was primarily based on clinically confirmed fluctuating weakness 
of voluntary muscles other than external eye muscles, the levator palpebrae or the orbicularis 
oculi, acquired after the age of 2 years, and the repeated absence of AChR antibodies in 
at least two assays. The diagnosis was considered to be confirmed electrophysiologically 
if a decrement of the compound muscle action potential of >10% had been found during 
repetitive nerve stimulation (RNS) or if single-fiber electromyography (SFEMG) had shown 
an increased jitter or blocking. 
Serum from all patients was retested for antibodies to the AChR, MuSK, voltage-gated 
calcium channels (VGCC) using radioimmunoassays (RSR Ltd., Cardiff, UK) and for creatine 
kinase (CK). In all SNMG patients, DNA was tested for the rapsyn N88K mutation. The 
sera were then also retested to identify antibodies to clustered AChR or overexpressed MuSK. 
For this, recombinant AChR subunits with rapsyn or recombinant MuSK full length were 
expressed in transfected human embryonic kidney (HEK) cells growing on coverslips. To 
identify the expressed AChR clusters or the MuSK on the cell surface, both rapsyn and MuSK 
were tagged with enhanced green fluorescent protein (EGFP). Serum sample was applied 
at the dilution of 1:20. Cells were fixed and human antibodies were visualised by anti-
human Alexa Fluor-labelled secondary antibody. Coverslips were examined on fluorescence 
microscope by two independent examiners using a semi-quantitative scoring system (0 to 
4). The average score was used to calculate the antibody levels with expressed recombinant 












































Inverted Kaplan-Meier curves were used to plot the cumulative incidence of symptoms during 
the 5 years following the first symptom. Statistical comparisons between the three groups 
were made using Pearson Chi-Square followed by Fisher’s exact tests for the proportion of 
patients that had a specific symptom already in the first month (t=0 to t=1), and using the 
log-rank test for the risk of developing each symptom between t=1 and t=60 months, i.e. 
during the first 5 years of follow-up. P-values were considered statistically significant below 
0.05 using the Bonferroni-Holm correction for multiple comparisons. A Cox proportional 
hazard model was then used to calculate the hazard ratios for each symptom to occur in 
the patients not presenting with that symptom. This model was also used to evaluate the 
matching for sex and age at onset between MuSK MG patients and AChR MG controls 
and to what extent these variables had influenced the comparison between MuSK MG and 
SNMG. All statistical analyses were performed using the SPSS 17.0 statistical software (SPSS 




In the 25 MuSK MG patients a female predominance was found (76%). Age at onset varied 
substantially between 6 and 74 years which was comparable to the range of the AChR MG 
controls although the mean age at onset was slightly higher in the MuSK MG group (Table 
3.1).
SNMG patients 
Of the 62 patients with SNMG described in the previous epidemiological study, 7 were lost 
to follow-up, no informed consent was obtained from 6, 1 patient had died and 1 16-year-
old girl had become AChR antibody positive three years after the onset of symptoms (Figure 
3.1). The remaining 47 were clinically re-examined. After the examination, 6 patients were 
excluded from the analysis because symptoms were incompatible with generalised MG (n=2), 
homozygous N88K rapsyn mutation (n=1), documented fluctuating weakness ever since the 
first day of life compatible with a congenital myasthenic syndrome (n=1), comorbidity in the 
form of severe Cushing’s disease before the onset of MG symptoms (n=1), and insufficient 
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Cell based assays
In the remaining 41 patients, characterisation of autoantibodies using the cell based assays 
yielded a further 10 patients with antibodies to the AChR, further referred to as ‘clustered 
AChR’ and 10 with autoantibodies to MuSK, further referred to as ‘overexpressed MuSK’. 
These results left 21 patients with generalised SNMG (Figure 3.1). For the 10 patients with 
antibodies to overexpressed MuSK, 2 patients were scored as 3, 7 patients as 2, and 1 patient 
as 1 using the semi-quantitative system and two independent examiners. For the 10 with 
antibodies to clustered AChR, 5 patients were scored as 1, one patient as 3, and 4 between 








































Figure 3.1 Inclusion and selection of sNMG patients 
New serum and DNA was obtained from all patients included in the clinical study at the time of the cross-
sectional examination. This serum was tested for antibodies to AChR and MuSK using radioimmunoassay (RIA). 
DNA was tested for the N88K rapsyn mutation. During the course of the study, cell-based assays became available 






































































Anti-Hu IgG Alexa Fluor Merged picture
Figure 3.2 Examples of positive samples for antibodies to Musk or aChr in the cell-based assays 
Left handed column shows transfected HEK cells with either overexpressed MuSK (4 rows at the top), or clustered 
AChR and rapsyn (4 rows at the bottom) tagged with enhanced green fluorescent protein (GFP). The middle 
column shows bound IgG visualised by anti-human Alexa Fluor-labelled secondary antibody from 4 SNMG 
patients (defined by RIA in the original cohort). The right handed column shows the merged pictures. Coverslips 
were examined by two independent examiners using a semi-quantitative scoring system (0 to 4). The first row 
of each section shows an example of patients who tested positive for MuSK (top) or AChR (bottom) in the RIA. 
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Clinical characteristics
Demographic and clinical characteristics of the 25 MuSK MG patients, 50 AChR MG 
controls and 21 patients with generalised SNMG are shown in Table 3.1. There was a female 
predominance in MuSK MG and SNMG. Age at onset and the number of patients with an 
onset in childhood were also similar. The indicated delay in diagnosis refers to the diagnosis 
of an acquired myasthenic syndrome, because in many patients the test for MuSK antibodies 
was not available at that time. The same applies for some of the older AChR MG patients 
with an onset before 1978. The wide range of the delay in the MuSK MG group is mainly 
due to one patient who had very prolonged static bulbar symptoms and atrophy of tongue 
and facial muscles for more than 30 years, following a relatively brief period of fluctuating 
ocular symptoms. One AChR patient had been treated with low dose prednisone for a 
suspected inflammatory myopathy between 1972 and 1981 before the diagnosis of MG was 
made. When excluding these two cases, the maximum delay was 5.9 years in the MuSK MG 
group and 4 years in the AChR MG group. At maximum disease severity, the MuSK MG 
patients were scored more often as predominantly bulbar (indicated by MGFA class IIb, IIIb 
or IVb), and twenty-eight percent required invasive ventilatory support at that time. By 
contrast, only one SNMG patient had required ventilatory support for one week after which 
symptoms resolved upon treatment with prednisone and azathioprine. Interestingly, this 
occurred at the age of 72 years, 40 years after the onset of the generalised symptoms. The 
majority of patients in all three groups had been treated with immunomodulating therapy 
at some point during the course of the disease. The severe involvement of bulbar symptoms 
in MuSK MG was also substantiated by a more frequent occurrence of severe weight loss 
compared to AChR MG and SNMG. However, in four AChR MG patients a predominantly 
bulbar phenotype was present as well, requiring nasogastric tube feeding without the need 










































Table 3.1 Demographical and clinical characteristics of three groups of MG patients
MuSK AChR SNMG
No. of patients 25 50 21
Women – n (%) 19 (76) 38 (76) 12 (57)
Non Caucasian - n (%) 3 (12) 2 (4) 0 (0)
Age at onset - median (range) in yrs 31.0 (6.0-74.5) 27.9 (4.6-78.3) 39.3 (5.9-66.8)
Age at onset below 16 yrs - n (%) 4 (16) 11 (22) 4 (19)
Delay in diagnosis - median (range) 0.7 (1m-33.1y) 0.5 (20d-9.9y) 1.6 (2d-13.0y)
Follow-up - median (range) in yrs 9.1 (1.2-33.8) 12.9 (0.9-41.2) 10.3 (0.8-45.5)
Duration to maximum (median and range in years) 1.1 (0.4-32.5) 1.1 (0-19.0) 3.3 (0-40.5)
MGFA at onset - n
- I 11 24 10
- II (b) 13 (8) 24 (9) 11 (2)
- III (b) 1 (1) 2 (1) 0 (0)
MGFA at maximum - n
- II (b) 1 (1) 5 (3) 9 (1)
- III (b) 9 (8) 29 (5) 9 (3)
- IV (b) 8 (7) 11 (4) 2 (1)
- V (%) 7 (28) 5 (10) 1 (5)
Number of MGFA V episodes







Weight loss more than >10% n (%) 16 (64) 14 (28) 3 (14)
Tube feeding n (%) (While not on respiratory support) 1 (4) 4 (8) 0 (0)
Immunomodulation (%) 22 (88) 43 (86) 13 (62)
Thymectomy (%) 9 (36) 31 (62) 5 (24)
Thymic hyperplasia according to pathology report (%) 1 (11) 12 (39) 1 (5)
Interval to immunomodulation (median and range in 
yrs)
0.9 (0.4-6.9) 1.3 (0.2-10.6) 3.1 (0-40.5)
Diagnostic tests in sNMG
In the SNMG patients, the diagnosis was confirmed by abnormal repetitive nerve stimulation 
or single-fiber EMG in 15 (71%). In three patients with incomplete EMG studies, a positive 
response to IV acetylcholinesterase inhibitors (AChEI) was seen. In one patient with a positive 
AChEI response, RNS and SFEMG studies were normal. In the remaining 2 patients all 
three tests had been negative, and the diagnosis of acquired MG had been based on clinically 
confirmed fluctuating oculobulbar weakness responding to oral immunosuppressive therapy. 
Serum CK levels were normal for all patients included. Antibodies to VGCC were absent.
Evolution of symptoms
First symptoms
The first symptoms reported by the patients did not discriminate between MuSK MG, AChR 
MG, and SNMG. Isolated diplopia or ptosis was most frequently reported at the onset of the 
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and in 43% of the SNMG group. In MuSK MG and AChR MG, the next frequently involved 
first symptoms were bulbar (20% in MuSK MG and 16% in AChR MG) and weakness of 
arms and legs (12% for MuSK MG versus 16% for AChR MG). In SNMG however, the 
next frequent first symptom was either simultaneous weakness in arms and legs (24%) or 
isolated weakness in the legs (19%). Two symptoms reported at onset only in MuSK MG 
were isolated neck weakness in two and severe dyspnoea in one. 
Symptoms in the first month
For symptoms occurring within the first month, Pearson’s Chi Square test showed a 
statistically significant difference between the three groups only for dyspnoea (p = 0.013) 
and proximal leg weakness (p = 0.029). Subsequent Fisher’s exact tests showed that this was 
due to a more frequent occurrence of proximal leg weakness in 48% of the SNMG patients 
compared to 12% of the MuSK MG patients (p = 0.01), and of dyspnoea in 4 MuSK MG 
patients compared to none of the AChR MG patients (p = 0.01). In the first month, proximal 
weakness of the extremities was more frequent in AChR MG patients than in MuSK MG 
patients (28% vs. 8% for the arms and 34% vs. 12% for the legs), although this failed to 
reach statistical significance (p = 0.071 and 0.054). None of the other studied symptoms 
showed any statistically significant differences between the three MG subtypes during the 
first month.
Progression of symptoms after the first month
The cumulative incidences of 14 symptoms in the three MG groups during the 60 months 
after the onset of symptoms are represented by inverted Kaplan-Meier curves in Figure 3.3. 
The more frequent occurrence of symptoms in MuSK MG, as compared to AChR MG, 
reached statistical significance for diplopia, (p = 0.017), dysphagia (p = 0.003), neck weakness 
(p = 0.0002), dyspnoea (p = 0.0008), and intubation (p = 0.007). After two years, 92% of 
MuSK MG patients had experienced a period of diplopia, compared to 64% of AChR MG 
patients and 71% of SNMG patients (71%). After 5 years of follow-up, 28% of the MuSK 
MG patients had needed respiratory support, compared to only 6% of AChR MG patients 
and none of the SNMG patients. By contrast, the frequent occurrence of ptosis was similar 










































Figure 3.3 Inverted kaplan-Meier plots indicating the cumulative incidences of 14 symptoms in the 
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SNMG emerged as a disease with early and frequent occurrence of ptosis, followed by 
diplopia and proximal weakness in the arms and legs. The following symptoms in SNMG 
patients were significantly less frequent: facial weakness (p = 0.001), dysarthria (p < 0.003), 
dysphagia (p < 0.001), neck weakness (p < 0.001), dyspnoea (p < 0.001) and intubation 
(p = 0.01). Cox proportional hazard ratios for the 14 symptoms are given in Table 3.2. These 
ratios indicate the risk for a symptom to occur after the disease had presented itself in the 
first month with other symptoms. Upon addition of the matching factors age at onset and 
sex the hazard ratios in the Cox model for the comparison between MuSK MG and AChR 
MG remained similar (median proportion of hazard ratios 0.96, range 0.88 to 1.12). For the 
comparison between MuSK MG and SNMG, the median proportion of hazard ratios before 
and after correction for age at onset and sex as was 0.94 (range 0.65 to 1.16). 
Table 3.2 Cox proportional hazard ratios for the 14 symptoms in patients with Musk MG compared 
to aChr MG and sNMG patients
MuSK MG compared to:
               AChR MG SNMG
Hazard ratio    p Hazard ratio      p
Diplopia 2.2 0.031 2.3 0.075
Ptosis 1.0 0.918 0.8 0.466
Facial weakness 1.4 0.264 4.9 0.004
Dysarthria 1.9 0.027 4.6 0.002 *
Dysphagia 2.0 0.017 6.9 <0.001 *
Weakness of chewing 0.7 0.367 2.9 0.063
Weakness of tongue 1.5 0.341 3.4 0.063
Weakness of neck 2.6 0.002 * 9.7 <0.001 *
Dyspnoea 2.4 0.018 9.7 0.003 *
Intubation 5.3 0.016 62.7 0.183
Arms proximal 1.0 0.888 0.9 0.859
Arms distal 0.6 0.287 5.8 0.1
Legs proximal 0.8 0.537 1.2 0.673
Legs distal 1.2 0.738 57.7 0.228
* P-value reaching statistical significance using the Bonferroni-Holms correction for 14 comparisons. Statistically 










































In Figure 3.4, median time interval between onset and the first occurrence of 13 symptoms 
in three MG subtypes is shown. In SNMG patients, the median for ptosis and proximal 
limb weakness was reached earlier than in MuSK MG or AChR MG. The median for bulbar 
symptoms (facial expression, speech, swallowing, chewing and tongue movements) was 
not reached for SNMG, because during the follow-up, less than 50% of SNMG patients 
developed any of these symptoms.
Figure 3.4 Median time interval between onset and first occurrence of 13 symptoms in MG subtypes 












































Extraocular symptoms had often disappeared at cross-sectional examination. Although 
diplopia had been present somewhere during the course of the disease in all but one patient, 
diplopia was absent in 17 patients and severe in only 3. Ptosis was also absent in 17 and 
severe in 1 patient. Thirteen patients (52%) did not have any ocular symptoms.
The most frequently involved bulbar symptom was dysphagia, (severe in 3 and mild in 12) 
and dysarthria (severe in 5 and mild in 8). Sixteen patients had reported a period of body 
weight loss of more than 10% in the course of the disease. One patient had required tube 
feeding. Facial weakness was found in 14 patients of whom 9 had atrophied facial muscles. 
The tongue was weak in 12 patients and atrophied in 7. The jaw muscles were least involved 
and just mildly weak in 2 patients. Ten patients complained of dyspnoea, mostly related to 
exercise and increasing in supine position, compatible with diaphragmatic weakness. Bulbar 
symptoms were absent in only 4 patients of whom two were in clinical remission, one had 
mild diplopia and neck weakness, and one had weakness of the neck and arms. 
Neck weakness was found in 68% of patients. Both isolated weakness of neck flexors (n=8) 
and neck extensors (n=1) was observed. Weakness of axial and limb muscles tested was 
symmetrical and within the MRC class 4 range except for 2 patients who could barely lift 
their head in prone position. 
The arms were affected in 13 patients of whom weakness was exclusively proximal in 6 and 
only affecting distal muscles in 2. In the legs, only hip flexors and foot extensors were mildly 
affected in 7 patients. Knee extension and foot flexion were always within the MRC 5 range 
although 4 patients showed fatigability and were unable to perform 20 squads. Isolated foot 
extensor weakness was found in three.
At cross sectional examination, only two patients were in clinical remission, one in complete 
stable remission and one in pharmacological remission while on azathioprine. All patients 
but three had received immunosuppressive therapy (20 prednisone, 8 azathioprine, 7 plasma 
exchange, 4 thymectomy, 1 IVIG). In five patients, post intervention status was unchanged 
at cross-sectional examination. One patient depended entirely on regular plasma exchange 
using an arteriovenous shunt. Twenty-two patients had received pyridostigmine, leading to 
a clinical improvement of weakness in only 4, but to muscle twitching in 17 patients.
SNMG (n=21)
Weakness was in general much milder in the SNMG group. Extra ocular symptoms 
predominated in all but three patients. Ptosis was found in 14 and diplopia in 7. Bulbar 
muscles were affected in 5 patients only. Three had mild dysphagia and dysarthria. One 
showed severe facial weakness with atrophy. One complained of mild dyspnoea. No patient 










































suffered from pneumonia caused by rotavirus at the age of 72 and more than 40 years after 
onset of MG symptoms. Three patients had experienced more than 10% weight loss in the 
course of the disease. 
Axial and limb muscles were all within the MRC grade 4 range. In the arms, proximal 
muscles were affected in 14 patients of whom 3 also had some distal weakness. In the legs 
proximal weakness was found in 12 of whom three had also distal weakness. 
The milder course of the disease was also reflected by a less frequent use of immunosuppressive 
therapy compared to MuSK MG or AChR MG. Nine patients had never received oral 
immunosuppressive therapy of whom 2 had been thymectomized. Of the remaining 12 who 
received prednisone (n=7) or azathioprine (n=5), the clinical response to treatment was clear 
in 7 and somewhat questionable in 3. At cross-sectional examination, twelve patients (56%) 
had no immunosuppressants any more. Pyridostigmine had been prescribed in all but one 
patient and had been effective in 16 (80%). Only one female patient had reported muscle 
twitching.
Overexpressed MuSK (n=10)
In patients who tested negative for MuSK antibodies in the conventional RIA, but positive 
in the cell-based assay (overexpressed MuSK), there was a female predominance (8 vs. 2). 
Eight patients had shown a clinical course typical for MuSK MG with predominant bulbar 
weakness, mild proximal weakness and mild transient ocular symptoms. The other two 
had shown limb-girdle weakness affecting the legs more than the arms. In general, the 
course of the disease had been milder than that of the MuSK MG group with exception 
of one female patient who developed severe respiratory insufficiency within three months 
after onset. Six had never received immunosuppressive therapy. Apart from one female who 
adjusted meals for dysphagia, and another whose limb-girdle weakness limited her activities 
like housekeeping, no limitations in daily life activities were reported. At cross-sectional 
examination, only mild residual weakness was found in a minority of patients. None had 
ocular symptoms and four showed mild bulbar weakness. The tongue was atrophied in one. 
Three had mild weakness in the arms, and two in the proximal legs. Three were still treated 
with low dose oral immunosuppressive therapy. All had been treated with pyridostigmine. 
This was beneficial in 4, without any effect in 5 and caused muscle twitching in one.
Discussion
In this retrospective study we compared the course of clinical symptoms in MuSK MG in 
the first 5 years to that of AChR MG in two cohorts matched for sex and age at onset. This 








































Clinical comparison of myasthenia gravis subtypes
43
study. The SNMG cohort could be defined more strictly than in the studies published to 
date by excluding patients with antibodies to clustered AChR or overexpressed MuSK using 
cell-based assays. Antibodies to MuSK or AChR were found in 48% of the SNMG patients 
originally defined by RIA and were also mutually exclusive.
The three MG subtypes could be distinguished on a group level by studying fourteen areas 
of muscle weakness. MuSK MG emerged as a disease with predominant bulbar and axial 
weakness, affecting both neck flexors and extensors and leading to respiratory crises in one 
third of the patients. Almost all patients experienced periods of extraocular weakness early 
in the course of the disease whereas this was not a frequent symptom later on. Within the 
group of bulbar muscles, those involved in chewing were less affected than the ones used in 
articulation, swallowing or facial expression. The relative resistance to weakness of masseter 
muscles has also been described in an MRI study of MuSK MG. 116 Muscle atrophy and 
hypersensitivity to AChE inhibitors occurred frequently. Clinical characteristics of the 
overexpressed MuSK group were similar to that of the MuSK cohort defined by RIA. We also 
observed patients in this group who became seropositive in the MuSK RIA later in the course 
of the disease. This indicates that the cell-based assay is indeed able to detect antibodies that 
are clinically relevant to the diagnosis. By contrast, weakness in SNMG was generally of a 
mild proximal limb-girdle distribution with prominent extraocular involvement.
On the individual level however, fulminant and severe bulbar weakness were also seen in 
the AChR group and even in one SNMG patient. This emphasizes the whimsical nature of 
MG and makes it impossible in our view to clinically differentiate between the subtypes in 
individual patients, especially early in the course of the disease.
The rarity of MG makes it impossible to study large cohorts in a prospective way. The long 
follow-up we were able to describe has the possible disadvantage of recall bias. Patients often 
have a clearer memory of the onset of ocular symptoms compared to proximal limb-girdle 
weakness. The fact that patients and clinical data had to be included from a nationwide study 
of AChR antibody negative MG made it impossible to blind the examiner for the diagnosis. 
We tried to limit this potential bias by structuring the interviews and collecting registered 
medical information from hospital files made at the time by their treating physicians. 
It remains questionable whether the selected SNMG patients represent a homogeneous 
entity. Patients with a congenital myasthenic syndrome rarely present at a later age, 45 We 
were able to identify one patient, homozygous for the rapsyn N88K mutation, who presented 
in his twenties, although careful history did reveal minor symptoms of weakness from early 
childhood. One copy of this mutation has been found in all late-onset patients described 
until now. 117 Although we did not sequence the Dok7 gene, a recent study of a large cohort 
of acquired SNMG patients did not find any copy of the common c.1124_1127dupTGCC 
mutation found in late-onset patients. 118 The response to immunosuppressive treatment 










































lipoprotein receptor-related protein 4 (LRP4) have been described in patients with SNMG. 
100-102 LRP4 is the agrin receptor activating MuSK. As extracellular protein it is a candidate 
to trigger autoimmune responses. Pevzner et al. used full length human LRP4 cDNA to 
transfect HEK293 cells and showed immunoreactivity of SNMG sera from 19 out of 38 
patients. 101 However, staining was also positive in one out of 11 MuSK MG patients, and 
SNMG was defined by conventional RIA only. The authors describe a high prevalence of 
bulbar weakness and female predominance similar to MuSK MG and state in the discussion 
that the LRP4 phenotype cannot be distinguished from AChR MG. Higuchi et al. reported 
LRP4 antibodies in 9 of 300 SNMG patients, but also in 3 of 28 MuSK MG patients, using 
precipitation assay in which the extracellular domain of LRP4 is conjugated to luciferase. 
100 Here too, LRP4 positive patients showed severe bulbar or limb weakness and SNMG is 
defined by RIA only. It is not stated if only patients with generalised MG were included. 
In view of the high rate of patients with antibodies to clustered AChR or overexpressed 
MuSK in our study, it seems likely that such patients may also be part of the aforementioned 
studies. Therefore, it is not yet clear if these antibodies represent an isolated MG subtype 
and are indeed pathogenic. Although we were unable to detect autoantibodies to LRP4 in 
our SNMG cohort using cDNA from rat (cowork with Coldefy and Burden, unpublished), it 
cannot be ruled out that LRP4 MG is another MG subtype within our SNMG cohort. 
In summary, the cell-based assays enabled us to refine the SNMG cohort by excluding 
nearly 50% of the patients who had antibodies to clustered AChR or overexpressed MuSK, 
showing more consistent limb-girdle weakness and ocular symptoms in the group of SNMG 
patients. Nonetheless, the pattern of weakness could vary significantly between individual 
patients, reflecting either the existence of multiple other antibodies to unknown antigens 
in the neuromuscular junction, late-onset congenital syndromes, or an unexplained intrinsic 
quality of myasthenia gravis in general.
IV
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The authors studied the HLA profile of 23 white Dutch patients with muscle-specific kinase 
antibody-positive myasthenia gravis (MuSK MG) and found an association with HLA-
DR14-DQ5 (odds ratio 8.5; 95% CI 3.9-18.7; p = 4.9 x 10-5). Fifty-two percent of the 
patients carried the DR14 allele compared to 5% percent of the controls (p = 1.0 x 10-8). 
This association between MuSK MG and a relatively rare HLA haplotype differs from the 
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Introduction
In approximately 90% of patients with generalised weakness, myasthenia gravis (MG) is 
caused by autoantibodies directed against the nicotinic acetylcholinereceptor (AChR). In 
30% to 40% of the patients with generalised MG without anti-AChR antibodies (AChR 
Ab- MG), antibodies against muscle-specific kinase (MuSK) can be found. MG with anti-
MuSK autoantibodies (MuSK MG) comprises a clinical phenotype with marked involvement 
of oculobulbar, neck and diaphragmatic muscles. 56 Anti-MuSK antibodies are mainly of the 
immunoglobulin (Ig) G4 subclass, instead of IgG1 and IgG3 in AChR MG. 93
The presence of other autoimmune diseases in patients with AChR MG and their first-
degree relatives suggests a role for a genetic predisposition of which the HLA genotype is 
the most well known. Early-onset AChR MG without thymoma is strongly associated with 
the HLA-A1-B8-DR3 haplotype in white Europeans. 20-22 DR16 and DR9 are also linked 
to AChR  MG in white French people. In this cohort, an association with polymorphisms in 
the gene encoding the α-subunit of the AChR as well as a decreased frequency of the DR7 
allele has been found. DR2 has been associated with late-onset AChR MG. We studied HLA 
polymorphisms in white Dutch patients with MuSK MG.
Methods
Between July 2003 and December 2004, patients known to have acquired generalised AChR 
Ab- MG from all eight University Medical Centres and five larger general hospitals in the 
Netherlands were included in a nationwide study of seronegative MG. Patients were selected 
using computerised diagnosis registrations and asked for informed consent by their attending 
neurologist. A single investigator (E.H.N.) re-examined all patients to assess present clinical 
symptoms. Course of the disease and evolution of clinical symptoms in time were evaluated 
retrospectively by taking a detailed history from each patient, the use of questionnaires and 
review of patients’ charts. Weakness during the onset of clinical symptoms and maximum 
disease severity was graded according to the Myasthenia Gravis Foundation of America 
(MGFA) clinical classification. The presence of other autoimmune diseases in the patients 
and their first-degree relatives was evaluated during the interview. Serum from all patients 
was obtained and retested for the presence of anti-AChR, anti-MuSK and anti-voltage-gated 
calcium channel (VGCC) antibodies in Leiden using commercial assays (RSR Ltd., UK) and in 
Oxford. DNA was isolated from peripheral white blood cells. HLA Class I and II typing was 
performed with the use of PCR-amplified fragments and biotin-labelled oligonucleotides as 
previously described. 119 DNA typed DRB1* and DQB1* alleles were translated throughout 










































committee. Frequencies of HLA alleles were compared to those of a previously published 
group of 2,440 healthy white Dutch blood donors. 120 Distribution of HLA haplotypes was 
compared to that of 321 individuals from the same control group available for haplotype 
assignment. For statistical analysis the two-sided Fisher exact test was used. p values were 
corrected for multiple informative comparisons conform the Bonferroni method. Odds ratios 
(ORs) with 95% CIs were calculated according to the Woolf Haldane test. All patients gave 
written informed consent before their participation. The Medical Ethical Committees of all 
hospitals involved approved the study.
results
Patient characteristics
Seventy-three patients with acquired generalised AChR Ab- MG were found in the 
Netherlands. Anti-MuSK antibodies were present in 26 of whom 23 white patients (18 
women and 5 men) were included. None of these patients had anti-AChR antibodies in 
at least two assays (range 2 to 14) performed in different laboratories. No anti-VGCC 
antibodies were found. The mean age at onset was 36.4 years (range 6.0 to 74.5 years). 
The mean duration of follow up was 10.4 years (range 1.2 to 33.9). The mean time from 
onset of symptoms until the first period of maximum disease severity was 1.8 years (range 
0.25 to 6.75), apart from one patient whose weakness was greatest 32 years after onset. 
Weakness at onset of symptoms was restricted to the extraocular muscles in 8 (MGFA Class 
I), predominantly bulbar in 10 (MGFA Class IIb or IIIb), mainly affecting the extremities 
in 2 (MGFA Class IIa) and mixed generalised in 3 (MGFA Class II). At maximum disease 
severity, however, bulbar and respiratory muscles were prominently involved in 15 patients 
(MGFA Class IIb, IIIb and IVb), with a further 7 requiring ventilatory support (MGFA Class 
V), leaving only 1 patient with severe mixed generalised weakness (MGFA Class IV). 
HLa association
The absolute and relative distribution of HLA polymorphisms in patients and controls 
were calculated (Table 4.1). A highly significant association was found with alleles DR14 
(52% vs. 5% in healthy controls) and DQ5 (78% vs. 35%). Nineteen of 23 patients carried 
either DR14, or DQ5, or both. The HLA-DR14-DQ5 haplotype was significantly increased 
among MuSK MG patients (p
c 
= 4.9 x 10–5, Table 4.2). The frequency of the DQ6 allele was 
decreased in MuSK MG (22% vs. 50%). There was no significant association with the B8-
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Table 4.1 Frequencies of HLa alleles in 23 patients with Musk ab+ MG.
HLA* MuSK n (%) Controls n (%) OR 95% CI p p
c 
§
A1 4 (17.4) 747 (30.6) 0.5225 0.1868 - 1.4616 0.2539 0.9778
B8 3 (13.0) 554 (22.7) 0.5809 0.1862 - 1.8117 0.3275 0.9974
DR3 2 (8.7) 599 (25.0) 0.3484 0.0937 - 1.2952 0.0885 0.6712
DR1 9 (39.1) 473 (19.7) 2.6601 1.1666 - 6.0657 0.0320 0.3235
DR14 12 (52.2) 127 (5.4) 18.8448 8.2956 - 42.8093 8.5 x 10-10 1.0 x 10-8 
DR16 2 (8.7) 43 (1.8) 6.1173 1.5960 - 23.4471 0.0701 0.5821
DQ5 18 (78.3) 300 (34.6) 6.3523 2.4271 - 16.6255 3.1 x 10-5 1.5 x 10-4 
DQ6 5 (21.7) 453 (50.1) 0.2960 0.1132 - 0.7736 0.0098 0.0482
* To allow comparison with a large control population that was typed serologically, DNA typed DR and DQ alleles 
were translated to their serological equivalents.
§ Corrected p value according to the Bonferroni method for multiple comparisons.
Table 4.2 Distribution of HLa-DQ5 associated haplotypes in patients and controls
HLA MuSK n (%) Controls n (%)* OR 95% CI p
c 
§
DR14-DQ5 11 (23.9) 23 (3.6) 8.5 3.9 - 18.7 4.9 x 10-5
DR1-DQ5 9 (19.6) 61 (9.5) 2.4 1.1 - 5.1 n.s.
DR10-DQ5 1 (2.2) 7 (1.1) 2.8 0.5 - 16.5 n.s.
DR16-DQ5 2 (4.3) 7 (1.1) 4.8 1.1 - 20.6 n.s.
* This control cohort consisted of 321 individuals available for haplotype assignment.
§ Corrected p value for multiple comparisons.
related autoimmune diseases
Five patients had another autoimmune disease: two had thyroid disease, one had vitiligo, 
and two had psoriasis. Four of these five patients carried the DR14-DQ5 haplotype. Eight 
patients had a first-degree relative with autoimmune disease: three with thyroid disease, 
one with vitiligo, three with rheumatoid arthritis, and one with psoriasis. The DR14-DQ5 
haplotype was found in three of these eight, and three patients had DQ5 in combination 
with DR1. Only one patient, whose first-degree relative had vitiligo, carried the B8-DR3 
ancestral haplotype. 
Discussion
We found a highly significant association in MuSK MG with HLA-DR14 and DQ5. This 
association is different from the known association of the B8-DR3 haplotype with early-
onset AChR MG. Our cohort of MG patients is representative of the MuSK MG patients 











































The HLA-DQ5 allele is in linkage disequilibrium with several HLA-DR alleles including 
DR1, DR10, DR14, and DR16. Although DQ5 as a group was significantly increased in 
MuSK MG, no significant association was found for the DR1-DQ5, DR10-DQ5, and DR16-
DQ5 haplotypes as shown in Table 4.2. The following DQ5 haplotypes can be observed: 
DQB1*0501 with DR1 and DR10, DQB1*0502 with DR16 and DQB1*0503 with DR14. 
These DQ5 molecules differ in their β-chains, which may influence antigen presentation. 
The association with DR14 is highly significant with an OR of 18.8, and we found one 
patient with DR14-DQ6, an extremely rare haplotype in white Dutch people, being absent 
in 321 healthy controls. Therefore, we speculate that the association is explained by the 
presence of the DR14-DQ5 haplotype rather than by DQ5 as a group.
DR14 is also associated with pemphigus vulgaris in non-Jewish white and Pakistani 
patients. 121,122 The DR14-DQ5 haplotype is even linked to the presence of pemphigus-
specific anti-desmoglein 3 antibodies in relatives of the Pakistani patients. Interestingly, 
in both pemphigus foliaceus and vulgaris, autoantibodies directed to desmoglein 1 and 
3 are mainly of the IgG4 subclass during periods of disease activity. 123 A predominance 
of the non-complement fixing IgG4 isotype is also found in MuSK MG. 93 In contrast, 
autoantibodies in AChR MG are mainly IgG1 and IgG3 isotypes and cause complement-
induced damage to the postsynaptic membrane. The association of MuSK MG and the HLA 
DR14-DQ5 haplotype adds to the previously described differences in clinical appearance and 
IgG subclass distribution of antigen-specific antibodies between MuSK MG and AChR MG, 
suggesting a different immunopathogenesis for both diseases. 
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We studied the longitudinal relation between disease severity and titres of antigen-specific 
IgG subclasses in sera of patients with myasthenia gravis and antibodies to muscle-specific 
kinase (MuSK MG). Six patients were included of whom 55 samples had been collected 
during 2.5-13.4 years. Anti-MuSK antibodies were determined by ELISA and with a cell-
based immunofluorescence assay. Disease severity was scored on a semi-continuous scale. 
Only antigen-specific IgG4, and not IgG1, titres were significantly associated with disease 
severity in a linear mixed effect model (p = 0.036). Levels of IgG4 antibodies were above 
IgG1 in all samples except in one patient who went into clinical remission while switching 
from IgG4 to IgG1. The results support an important role for IgG4 in the pathogenesis of 
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Introduction
Myasthenia gravis with autoantibodies against muscle-specific kinase (MuSK MG) is a 
rare disorder of neuromuscular transmission predominantly affecting craniobulbar and 
respiratory muscles. 56 In mice, MuSK is involved in the organisation and maintenance of the 
neuromuscular junction through clustering of postsynaptic acetylcholine receptors (AChR). 
65 Immunization of mice with the extracellular domain of the MuSK receptor induces a 
postsynaptic neuromuscular transmission disorder with exercise-induced weakness. 124 In 
mammalian muscle, RNA interference with MuSK induces the disassembly of existing 
neuromuscular junctions underscoring the role of MuSK in synapse maintenance. 66 The 
deficiency of synaptic transmission can be confirmed by EMG showing a decrement of the 
compound muscle action potential upon repetitive nerve stimulation or an increased jitter 
in single-fiber EMG. In MuSK MG autoantibodies are predominantly of the IgG4 subclass, 
although IgG1 autoantibodies are also present. 93 This is in contrast to myasthenia gravis with 
anti-acetylcholine receptor antibodies (AChR MG), where IgG1 and IgG3 autoantibodies 
cause postsynaptic complement deposition, AChR depletion and structural damage to the 
neuromuscular synapse. Such histological abnormalities have not been found in patients 
with MuSK MG 125 and it has been suggested that anti-MuSK antibodies may not be the 
primary cause of myasthenic symptoms. 126 In order to define better the pathogenic role of 
these antibodies, we investigated the longitudinal association between titres of anti-MuSK 
specific IgG subclasses and disease severity in MuSK MG. 
Patients and methods
Patient selection
All consecutive patients with MuSK MG, registered prospectively in our centre since 1990, 
were included who had been followed clinically for more than three years and from whom 
multiple serum samples were available. Samples had been collected for future research 
throughout the period of clinical follow-up. Presence of anti-MuSK antibodies and absence 
of anti-AChR antibodies were confirmed using standard commercial assays (RSR Ltd., 
Pentwyn, Cardiff, UK).
Disease severity score for grading clinical symptoms
Severity of MG symptoms was evaluated retrospectively and independently by two 
neurologists with extensive clinical experience in neuromuscular disorders (PWW and 
ARW). Both neurologists were blinded for the anti-MuSK antibody titres. They were 










































patients’ charts to evaluate the severity of symptoms on that date. The Disease Severity Score 
(DSS) was a semi-continuous variable between 1 and 5, allowing regression analysis. The 
definitions of the units in this scale, shown in Table 5.1, were modified after Oosterhuis et 
al. 37 in combination with the grading system of bulbar symptoms according to Brooke. 127 
Tenth-values were used to allow scoring of subtle fluctuations of disease severity. The results 
of the DSS which were used for the statistical analyses were based on consensus between the 
two neurologists. Symptoms on each time point were also classified according to the MGFA 
clinical classification. 113 This scale was not used for statistical analyses because of its ordinal 
feature.
Table 5.1 Definition of units for the Disease severity score (Dss)
1 Complete remission, no signs after exertion, no complaints. Speech and swallowing are normal
2 Minor signs or minor complaints. No disability. The experienced doctor may find minor signs at 
appropriate testing. Speech or swallowing may be abnormal but do not cause practical problems
3 Moderate disability. Clear signs after exertion. Some restrictions in daily life. Speech is difficult to 
understand. Swallowing may cause choking
4 Severe disability, clear signs at rest. Restrictions in domestic activities. Speech is intelligible for 
relatives or close friends but unintelligible for others. Difficulties with swallowing are constant and 
meals have to be adapted. Decreased respiratory function may be present
5 Respiratory support
ELIsa for anti-Musk specific IgG antibodies
Maxisorp plates (96 well, NUNC, Roskilde, Denmark) were coated overnight at 4 °C 
with 100 μl/well of 0.4 μg/ml of the extracellular domain of human MuSK 93 dissolved in 
phosphate buffered saline pH 7.2 (PBS) and blocked for 1 hour at room temperature (RT) 
with 150 μl/well 2% Casein in PBS with 0.05 % Tween (PBS/C/T).
The plates were incubated with 3-fold serial dilutions of serum samples and standards, 
starting with a 1:50 dilution, in PBS/C/T for 2 hours at RT. For the detection of total 
IgG anti-MuSK, the plates were incubated for 2 hours at RT with alkaline phosphatase-
conjugated goat-anti-human IgG (1:2000, Invitrogen, Carlsbad, California, USA). Anti-
MuSK antibodies in the different IgG subclasses were measured by a two hours incubation 
at RT with specific monoclonal antibodies (IgG1, MH 161-1, Sanquin, Amsterdam, The 
Netherlands; IgG2, HP6014; IgG3 NI86; IgG4 NI315, Nordic, Tilburg, The Netherlands), 
followed by incubation overnight at 4 °C with alkaline phosphatase-conjugated rabbit 
anti-mouse Ig (1:750, Dakopatts, Glostrup, Denmark). After incubation with substrate 
(p-nitrophenylphosphate) in 0.01 M diethanolamine buffer pH 9.8 containing 1 mM MgCl
2
, 
the reaction was stopped with 3 M NaOH. The optical density (OD) at 405 nm was recorded 
with a Versamax microplate reader. Standard curves and calculations were made using the 
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anti-MuSK antibodies, expressed as arbitrary units (AU) per ml, was calculated by comparison 
with calibration lines from serial dilutions of a serum sample from a severely affected MuSK 
MG patient, not included in the present study. This serum contained relatively high titres of 
anti-MuSK specific IgG1 and IgG4 antibodies and was used as an internal standard.
Comparison of ELIsa titres of anti-Musk specific IgG subclasses
OD values obtained by using four different monoclonal mouse antibodies, each specific for 
one of the four human IgG subclasses, represent the relative quantities of the bound human 
IgG subclass as a proportion of that subclass in the internal standard. Because the exact molar 
concentrations of the anti-MuSK specific IgG subclasses in the standard serum are unknown, 
anti-MuSK specific IgG1 and IgG4 arbitrary units cannot simply be compared. To enable 
such a comparison and, thereby, calculation of the true ratios of the anti-MuSK specific IgG 
subclasses, sera of MuSK MG patients containing nearly only anti-MuSK specific IgG4 with 
a negligible quantity of IgG1 were selected. We postulated that the anti-MuSK specific 
IgG4 titres in these sera were equal to the total anti-MuSK specific IgG titres. The average 
ratio of anti-MuSK specific total IgG versus IgG4 was 0.99 and this conversion factor was 
used to adjust the anti-MuSK specific IgG4 titres in sera of the included patients. 
Similarly, a pool was constructed consisting of sera with the highest anti-MuSK specific 
IgG1 titres. Because, even in this pool, IgG4 could not be neglected, we postulated the 
sum of anti-MuSK specific IgG1 and IgG4 to be equal to the total anti-MuSK specific IgG 
titre. The average ratio of anti-MuSK specific total IgG versus IgG1 after subtraction of the 
IgG4 titre yielded a factor of 0.09, which was then used to adjust the IgG1 titres of the sera 
of the included patients. The adjusted titres were used to calculate the anti-MuSK specific 
IgG4/IgG1 ratios in these sera and to graphically represent anti-MuSK specific IgG1 and 
IgG4 titres on the same scale.
Cell-based immunofluorescence assay for anti-Musk specific IgG antibodies
HEK 293 cells were grown on coverslips and transiently transfected using polyethylenimine 
(PEI) with MuSK DNA tagged with enhanced green fluorescent protein (EGFP). 
Immunofluorescence staining was performed approximately 48 hours after transfection. The 
coverslips were incubated with patient or control sera (1:20 for total IgG and 1:20, 1:60 and 
1:180 for IgG1 or IgG4) for 1 hour at room temperature (RT). Cells were washed, fixed with 
3% formaldehyde in PBS for 15 minutes at RT. For the detection of total IgG antibodies, cells 
were incubated with goat anti-human IgG-Alexa Fluor 568-conjugated antibody (Invitrogen-
Molecular Probes, Paisley, UK) at 1:750. For the IgG subclasses, cells were first incubated 
with mouse anti-human IgG1 or mouse anti-human IgG4 (Binding site, Birmingham, UK) 
at 1:50, for 1 hour at RT, and then with goat anti-mouse isotype specific IgG-Alexa Fluor 










































for 45 minutes at RT. Coverslips were mounted on slides in fluorescence mounting medium 
(DakoCytomation) with DAPI (4,6-diamidino-2-phenylindole) to counterstain nuclei. They 
were examined and imaged on a fluorescence microscope (Olympus, London, UK) with a 
digital camera Hamamatsu and Openlab imaging software (both provided by Improvision, 
Coventry, UK). 
Calculation of cell-based titres of anti-Musk specific IgG subclasses
The complete coverslip was checked for stained cells. They were coded and scored for the 
frequencies and intensities of surface binding by the human/mouse IgG antibodies. We used 
the following scoring system systematically for every coverslip: (0) = no labelling; (0.5) = 
very weak labelling of very few transfected cells with no obvious co-localisation; (1) = weak 
labelling of some of the transfected cells, with co-localisation; (2) = moderate labelling of 
some (~ 20-50%) of the transfected cells, with precise co-localisation; (3) = moderate/strong 
labelling of ~50%-80% of the transfected cells, with perfect co-localisation; (4) = strong 
labelling of virtually all transfected cells, with perfect co-localisation. The final score was 
the mean value of two scores by two different experienced people blinded for the condition 
(control or patient) and for antibody titres. The ratio between IgG4 and IgG1 anti-MuSK 
antibodies was calculated by dividing the final scores for the optimal dilution.
statistical analysis
A linear mixed effect model was used to asses the associations on group level between anti-
MuSK specific IgG1, IgG4 and total IgG titres (on a log scale) and the DSS. This model 
takes into account multiple measurements per patient and the variability in the number of 
measurements between patients. P-values for this model were calculated with the Wald test. 
Linear regression analyses were also performed for each patient separately. The interobserver 
variability of the independent DSS scores was expressed as a coefficient of variation (CV). 
This CV was calculated as the standard deviation of the two neurologists’ scores for each time 
point divided by the mean of these scores and multiplied by 100 to present as percentage. The 
level of agreement between the two independent scores for every coverslip in the cell-based 
assay was expressed by the intraclass correlation coefficient. All calculations were performed 
for adjusted and non-adjusted ELISA titres using the SPSS 14.0 Statistical software (SPSS 
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results
Three men (patients A, D and F) and three women (patients B, C and E) were included. 
Mean age at onset of symptoms was 32.4 years (range 18.7 to 43.2). Fifty-five samples were 
available (range 7 to 12 per patient) covering a mean period of 4.7 years (range 2.5 to 13.4). 
The interval between the onset of symptoms and the first available sample varied from 6 
months (patient B) to 33 years (patient F). All patients had predominantly oculobulbar 
symptoms (MGFA class IIb, IIIb, IVb and V) if not in clinical remission. 
Anti-MuSK antibodies were mainly IgG4 in all patients except for patient B who made 
a class switch from IgG4 to IgG1 while going into clinical remission. The mean ratio of 
adjusted IgG4/IgG1 titres for all patients was 18 (range 2 to 62). None of the patients 
had detectable anti-MuSK specific IgG2 or IgG3 antibodies. The linear mixed effect model 
showed a significant association between adjusted IgG4 titres and DSS on a group level 
(β coefficient 0.44, p = 0.036), whereas no association was found for adjusted IgG1 titres 
(β coefficient -0.32, p = 0.13). Total IgG was weakly associated with DSS (Table 5.2). 
Intraindividually, a positive correlation between anti-MuSK specific IgG4 and the DSS was 
found in 5 of the 6 patients, but not in patient C. Slopes varied from 0.01 to 0.15 reaching 
statistical significance in 3 patients (p < 0.05, Table 5.2). 
Table 5.2 Disease severity score versus adjusted antibody titres
β coefficient (p-value)
IgG4 IgG1 IgG total
Group level 0.44 a (0.036)* -0.32 a (0.134) 0.619 a (0.075)
Per patient A 0.146 (0.064) -2.576 (0.333) 0.078 (0.322)
B 0.060 (<0.001)* -0.078 (0.238) 0.068 (0.000)*
C -0.003 (0.918) 0.269 (0.641) -0.001 (0.988)
D 0.014 (0.004)* 0.358 (0.015)* 0.018 (0.054)
E 0.010 (0.021)* 0.220 (0.193) 0.008 (0.015)*
F 0.013 (0.066) 0.102 (0.552) 0.014 (0.074)
Correlation coefficients representing the relations between the Disease Severity Score and adjusted titres of anti-
MuSK specific IgG4, IgG1 and total IgG on group level and individually. a β-coefficient on a log scale. * p < 0.05.
The apparent correlation in the other two (patient A and F) failed to reach statistical 
significance. IgG1 was correlated with DSS only in patient D. In this patient relatively 
high IgG1 titres correlated with a low DSS. Regression slopes and p values were similar 
for adjusted and non-adjusted titres (data not shown). The correlations between DSS and 
adjusted titres of anti-MuSK specific IgG1 and IgG4 for each patient are shown in Figure 
5.1. The interobserver variability of the DSS varied between patients from 3.6% to 26.2% 










































Figure 5.1 The Disease severity score (Dss) versus adjusted titres of anti-Musk specific IgG1 and 




The Disease Severity Score (DSS) versus adjusted titres of antiMuSK specific IgG1 and 
Ig 4 in arbitrary units (AU) per ml in 6 patients 
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The Disease Severity Score (DSS) versus adjusted titres of antiMuSK specific IgG1 and 
IgG4 in arbitrary units (AU) per ml in 6 patients 
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Detailed graphical representation of the course of the DSS, adjusted anti-MuSK antibody 
titres, and the various immunosuppressive treatments per patient are shown in Figure 5.2. 
All patients had been treated with oral immunosuppressants somewhere during follow-
up. Duration of this therapy varied between 38% (patient B) and 100% (patients A, C 
and D) of the follow-up period. Two patients (C and D) received a single IVIG treatment. 
Three patients were treated with plasma exchange (A, B and F). Patient A and B were 
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Figure 5.2 Course of Disease severity score (Dss) and adjusted anti-Musk specific IgG1 and IgG4 




 Course of Disease Severity Score (DSS) and adjusted antiMuSK specific IgG1 and IgG4 
titres in AU/ml during followup  
 = IgG1,  = IgG4,  = DSS,  = Oral immunosuppression 
PE = Plasma exchange, TX = Thymectomy, IVIG = Intravenous Human Immunoglobulin 
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The highest titres of IgG1 in our study were detected in patient B. However, when this female 
patient presented with severe oculobulbar weakness in 1996, anti-MuSK antibodies were 
predominantly IgG4 (adjusted IgG4/IgG1 ratio 14). After thymectomy and treatment with 
plasma exchange followed by prednisone for 6 months and azathioprine for 4 years, she was 
in complete clinical remission in 2001. By then, anti-MuSK antibodies were predominantly 
IgG1 with an adjusted IgG4/IgG1 ratio of 0.2. During the next 4 years, this ratio fluctuated 










































An example of the use of tenth-values in the DSS, indicating small differences in clinical 
symptoms, can be observed in patient D. His bulbar symptoms were compatible with DSS 
category three and too mild for category four, because his speech was still intelligible and 
meals did not have to be adapted (Table 5.1). After an IVIG treatment in July 2005, he 
experienced a gradual speech improvement. He could eat his meals quicker than before and 
reported less shortness of breath at night. Nevertheless, speech and swallowing still caused 
practical problems and some disability, thereby exceeding category two. The use of tenth-
values allowed to score this clinical improvement as a decline in the DSS from 3.8 in July, to 
3.6 in August, and 3.4 in September 2005.
To confirm the IgG4 predominance and the changes over time, we used the cell-based 
immunofluorescence assay, which yielded IgG4/IgG1 ratios of 0.4 to 7, similar to those 
of the non-adjusted ELISA titres (mean ratio 2, range 0.2 to 6). The intraclass correlation 
coefficient for the two independent scores was 0.96 (p < 0.001). The class switch in patient 
B was also confirmed by immunofluorescence, yielding IgG4/IgG1 ratios of 3 (1996), 0.4 
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Figure 5.3 specific binding of IgG antibodies (red) to Musk-EGFP on HEk cell surface (green). 
A switch from IgG4 to IgG1 anti-MuSK antibodies is shown in three different serum samples from patient 
B, collected when the patient was severely affected in 1996 (A), and during clinical remission in 2001 (B), and 
2003 (C). Stainings are shown for total IgG (1:20), already merged (left), IgG1 (1:60) and IgG4 (1:20) antibodies. 











































In this study, anti-MuSK antibodies were mainly of the IgG4 subclass compared to IgG1. 
Only anti-MuSK specific IgG4 titres significantly correlated with disease severity on a group 
level. None of the patients included in this study had IgG2 or IgG3 antibodies against 
MuSK. IgG2 and IgG3 anti-MuSK antibodies were only detected at low titres in sporadic 
serum samples of a limited number of MuSK MG patients in the Netherlands (data not 
shown). Anti-MuSK specific IgG1 correlated with disease severity only in patient D, but the 
extremely low titres suggest that this correlation is not of clinical significance. 
Unfortunately, we could only include 6 patients in this longitudinal study. MuSK MG is 
a rare disorder which limits the feasibility of large scale prospective research. In spite of 
the small number of patients we were able to demonstrate an association between disease 
severity and anti-MuSK specific IgG4 titres. Another possible limitation is the retrospective 
quantification of the disease severity using a newly developed clinical scale that may have 
introduced a subjective element. However, existing scales such as the MGFA clinical 
classification have not been designed to measure outcome and lack quantification. 113 As 
an ordinal scale, the MGFA clinical classification is not suited for correlation or regression 
analyses. The quantitative MG score, designed for prospective follow-up, is less suited for 
patients with predominantly craniobulbar weakness. The DSS provided a possibility to grade 
smaller fluctuations of symptoms. In general practice, these are often indicated by patients and 
can be of great importance for clinical decision making. We limited the subjective element 
by the use of two experienced neurologists who scored the disease severity independently. 
The considerable level of agreement between these independent scores and the significant 
association with IgG4 autoantibody titres both imply that the scale was a useful instrument 
for the retrospective grading of clinical symptoms in patients with MuSK MG.
A correlation between clinical symptoms and total IgG titres of anti-MuSK antibodies has 
been reported by others. 128 In this study, results of patients included with a single sample 
and of those included with multiple samples are combined, making it somewhat difficult to 
discriminate between an interindividual and intraindividual relationship. In AChR MG the 
interindividual correlation between symptoms and autoantibody titres is weak in contrast 
to the intraindividual correlation. 37 The predominance of IgG4 anti-MuSK antibodies in 
MuSK MG has been described previously although up to 30% of anti-MuSK antibodies was 
IgG1. 93 
An IgG4 immune response is mainly seen after chronic antigen exposure, for example in the 
humoral response of beekeepers to bee venom. 129 Examples of IgG4 mediated autoimmune 
diseases are acquired hemophilia A, 130 latent autoimmune diabetes, 131 sclerosing pancreatitis, 
132 and pemphigus vulgaris (PV). 123 In PV patients with active disease IgG1 and IgG4 
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with prolonged disease remission, mainly IgG1 autoantibodies against one of these epitopes 
were found. 123 The authors propose that class switching may be involved in fluctuations of 
disease severity although no patients with longitudinal follow-up were included. In another 
study in which sera of 7 pemphigus patients collected during disease exacerbations and 
remissions were investigated, no evidence for such a class switch was obtained. 133 Therefore, 
the remarkable switch from IgG4 to IgG1 autoantibodies with a simultaneous clinical 
remission of MuSK MG in patient B seems a possible but not unique mechanism for disease 
fluctuations in antibody mediated autoimmune disorders. IgG4 is a functionally monovalent 
antibody, unable to crosslink or activate complement. Hence, the pathogenic mechanism of 
IgG4 antibodies to MuSK is more likely to be a direct effect on MuSK receptor function in 
contrast to the complement mediated destruction of the neuromuscular junction mediated 
by IgG1 and IgG3 autoantibodies in AChR MG. The results from this study provide an 
argument for the pathogenic role of IgG4 autoantibodies in MuSK MG although further 
studies are required to clarify how these autoantibodies interfere with signal transmission in 
the neuromuscular junction.
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In myasthenia gravis (MG), the neuromuscular transmission is impaired mainly by auto-
antibodies against the acetylcholine receptor (AChR). In about 5% of the MG patients, 
however, the auto-antigen is still unknown. We investigated whether these seronegative MG 
patients (SNMG) have auto-antibodies against ErbB proteins, which influence the AChR 
density at the NMJ. Using Fluorescence-activated cell sorting (FACS) and dot blotting 
analysis of membrane extracts from transfected human embryonic kidney (HEK) cells, we 
were unable to detect anti-ErbB antibodies in sera of SNMG patients. The results do not 
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Introduction
Myasthenia gravis (MG) is an acquired autoimmune disease that affects the synaptic 
transmission between motor neurons and skeletal muscle cells. In about 85% of generalised 
MG patients, autoantibodies are present against the acetylcholine receptor (AChR), which 
is located at the postsynaptic membrane of the neuromuscular junction (NMJ). 9 In about 
5% of the generalised MG patients the muscle-specific kinase (MuSK) is the target of 
the autoantibodies while antibodies to AChR are absent. 54 The remaining patients with 
generalised MG without detectable autoantibodies show symptoms that are similar to those 
presenting with anti-AChR positive MG. 134 These seronegative MG (SNMG) patients 
improve after immunosuppressive treatment, which strongly suggests that SNMG also has 
an autoimmune origin. 111,135 Approximately half of the SNMG subgroup appears to have 
antibodies to the AChR as well, although probably only with low affinity. 136 In a study by 
Leite et al. anti-AChR antibodies could only be detected by assays where the AChRs were 
clustered on the cell surface instead of being in a solubilised form, as is the case in routine 
assays for anti-AChR antibodies. 44 However, in about 5% of MG patients the auto-immune 
target remains unknown. We therefore tested the possibility that ErbB proteins can act as 
auto-antigens in SNMG.
ErbB proteins are receptors for neuregulins and are involved in the local activation of synaptic 
gene expression, such as AChR. 137,138 The ErbB receptor family consists of four members: 
ErbB1 (also known as the epidermal growth factor receptor or HER1), ErbB2 (also known as 
HER2 in humans and Neu in rodents), ErbB3 (or HER3) and ErbB4 (or HER4). In skeletal 
muscle, ErbB3 is expressed mainly at the terminal Schwann cells, whereas ErbB2 and 
ErbB4 are located postsynaptically in the depth of the folds. 137,139,140 Mutant mice lacking 
neuregulin or ErbB genes die early in embryogenesis due to defects in cardiac and neural 
development, but hemizygous mice are viable. 141,142 Mice hemizygous for the neuregulin-1 
gene have a reduced concentration of AChRs and show myasthenic symptoms 143,144, while 
mice hemizygous for the ErbB2 or ErbB3 gene show modest but significant postsynaptic 
defects, but no clear cardiac defects. 145 As transmembrane proteins, ErbB receptors are 
potentially accessible to antibodies and could act as autoantigens in an antibody-mediated 
immune response. Therefore, we studied the presence of antibodies to ErbB receptors in 












































Patients with generalised MG without anti-AChR antibodies were included from a nationwide 
study as described previously. 115 The diagnosis of generalised MG was based on acquired 
and clinically confirmed fluctuating weakness of muscles not restricted to the external eye 
muscles, the m. levator palpebrae or the m. orbicularis oculi. Absence of antibodies to the 
AChR in standard radioimmunoassays (RIA) was required more than once during periods 
of clinical weakness. The diagnosis was considered to be supported by a clinical response 
to intravenous acetylcholinesterase inhibitors or by electromyography if a decrement of the 
compound muscle action potential of >10% was found during repetitive nerve stimulation 
or if single-fiber electromyography had shown an increased jitter or blocking.
All patients were re-examined by a single investigator (EHN) for standardised history 
taking and physical examination. The clinical condition during the first two weeks and at 
maximum disease severity was classified according to the MGFA Clinical Classification. 113 
Serum from all patients was retested for antibodies to the AChR, MuSK and voltage-gated 
calcium channels in standard RIA (RSR Ltd., UK). DNA of SNMG patients was tested for 
the rapsyn N88K mutation known to cause a late-onset congenital myasthenic syndrome. 45
Of the 62 patients with SNMG originally described in our epidemiological study, seven were 
lost to follow-up, while no informed consent was obtained from six, one patient had died 
and one 16-year-old girl had become AChR antibody positive three years after the onset of 
the symptoms. The remaining 47 patients were clinically re-examined. Subsequently, five 
patients were excluded because the symptoms were incompatible with generalised MG (n=2), 
or because of the presence of a N88K rapsyn mutation (n=1), or comorbidity in the form of 
severe Cushing’s disease before the onset of MG symptoms (n=1), or finally because one patient 
appeared to have presented fluctuating weakness ever since birth (classified as congenital 
myasthenic syndrome, n=1). Clinical characteristics of 42 patients with generalised SNMG 
are summarised in Table 6.1. Muscle weakness was mild or moderate, and more of the limb-
girdle type (MGFA class IIa or IIIa). However, a few patients suffered from oculobulbar and 
axial weakness, even requiring intubation in two cases (MGFA class V). The diagnosis was 
supported by repetitive nerve stimulation in 14 patients, by single-fiber electromyography 
in 17 patients and by IV acetylcholinesterase inhibitor in eight patients. In one patient, 
diagnostic procedures were incomplete. Only repetitive nerve stimulation was performed 
but negative. In the remaining two patients, results of repetitive nerve stimulation, single-
fiber electromyography and IV acetylcholinesterase inhibitor were all negative. In all three 
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Table 6.1 Characteristics of 42 sNMG patients
Women - n (%) 28 (67)
Age at onset - median (range) in yrs 38.1 (5.9 - 66.8)
Age at onset below 16 yrs - n (%) 5 (12)
Follow-up - median (range) in yrs 10.4 (0.6 - 45.5)
Caucasian - n (%) 40 (95)
MGFA at onset
- I - n 19
- II (a vs. b) - n 23 (14 vs. 6)
MGFA at maximum or before thymectomy for French patients
- II (a vs. b) - n 20 (11 vs. 2)
- III (a vs. b) - n 15 (9 vs. 4)
- IV (a vs. b) - n 3  (0 vs. 2)
- V - n 2
Interval onset to maximum - median (range) in yrs 2.1 (0 - 40.5)
Diagnosis supported by 
- A. Electromyography - n (%) 31 (74)
- B. Response to IV AChE inhibitors - n (%) 8 (19)
- Neither A or B - n (%) 3 (7)
Therapy
- Oral AChE inhibitors - n (%) 41 (98)
- Immunomodulative therapy - n (%) 26 (62)
              - Oral immunosuppression - n (%) 23 (55)
              - Thymectomy (with follicular hyperplasia) - n 11 (3)
Interval onset to start of immunomodulation - median (range) in yrs 2.4 (0 - 40.5)
Fluorescence-activated cell sorting (FaCs)
Sera from 42 SNMG patients were screened for anti-ErbB-IgG using FACS. For this purpose 
murine 32D hematopoietic cells transfected with distinct combinations of human ErbB 
receptors were used. In the present study we used 32D13 cells (expressing both ErbB1 
and ErbB3), 32D23 cells (expressing both ErbB2 and ErbB3) and 32D24 cells (expressing 
both ErbB2 and ErbB4). Transfected 32D cells were cultured in RPMI 1640/glutamax-I, 
containing penicillin (100 U/ml), streptomycin (100 μg/ml), 10% fetal calf serum (FCS), 50 
μM β–mercaptoethanol, recombinant mouse IL-3 (0.5 ng/ml, R&D systems, Minneapolis, 
MN, USA), geneticin (G418, 600 μg/ml) and hygromycin B (for 32D13 and 32D23 cells, 
400 μg/ml). The cells were cultured in a 37°C humidified atmosphere containing 95% air 
and 5% CO2. High density 32D cells were harvested and resuspended in washing buffer 
(PBS containing 1% BSA/1% FCS/0.2% NaN3). Subsequently cells (0.15x106) were 
incubated with sera diluted to a final concentration of 1:10, 1:20 and 1:40 in washing buffer 
for 1 hour while gently shaking. Cells were then washed five times with washing buffer and 
incubated for 30 min with rabbit anti-human-IgG-FITC conjugate (1:20, Dako, Glostrup, 










































analysed according to the same protocol. The expression of ErbB2 was checked with a mouse 
monoclonal anti-c-ErbB2 (clone L26, Immunologic, Duiven, The Netherlands) and goat 
anti-mouse Ig-APC conjugate (BD Pharmingen, San Jose, CA, USA). Cell lines 32D23 and 
32D24 were positive for ErbB2 staining in contrast to 32D13 which was negative. FACS 
analysis was performed using a BD Biosciences FacsCalibur flowcytometer and the mean 
fluorescence intensity (MFI) was calculated with CellQuestPro software (BD Biosciences, 
San Jose, CA, USA). The MFI of each sample was normalised by dividing the obtained 
fluorescence values by the mean of the corresponding NHS group. The mean value of NHS 
plus two and three times the standard deviation was used as cut off value.
Dot blotting
Sera from 42 SNMG patients were also screened for anti-ErbB-IgG using dot blotting. 
For this, we used human embryonic kidney (HEK) 293 cells, transiently transfected with 
expression vectors for human ErbB2 and ErbB4 genes using the Profection mammalian 
calcium phosphate transfection system (Promega Corporation, USA). These vectors were 
a kind gift of Dr. L. Schaeffer from the ‘Laboratoire de biologie moleculaire et cellulaire’ 
in Lyon, France. Transfected cells were maintained in Dulbecco’s modified Eagle’s medium 
(DMEM) with glucose and sodium pyruvate (Gibco, Invitrogen Corporation, Breda, The 
Netherlands) supplemented with 10% FCS (Bodinco, The Netherlands), 1% penicillin/
streptomycin (Gibco) and 1% L-glutamine (Gibco). The cells were cultured in a 37°C 
humidified atmosphere containing 95% air and 5% CO2. After 72 hours, membrane proteins 
were isolated from the cells with a 0.6% cholate extraction buffer, containing 0.01 M NaN3 
(Acros Organics, Geel, Belgium), 0.01 M EDTA (Sigma-Aldrich, St-Louis, USA), 0.01 M 
iodoacetamide (Sigma), 0.1 mM phenylmethylsulphonyl fluoride (Sigma) and 0.6% cholate 
(Sigma) in PBS. The protein concentration was measured using the Bio-Rad system (Bio-
Rad, California, USA). To verify the expression of ErbB2 and ErbB4 in transfected HEK 
cells, Western blotting was performed as described before using rabbit anti-ErbB2 antibody 
(C-18) (sc-284, Santa Cruz Biotechnology Inc., USA) or of rabbit anti-ErbB4 antibody (C-
18) (sc-283, Santa Cruz).146
To detect anti-ErbB antibodies in sera of SNMG patients, 5 µl of ErbB transfected HEK 
293 cell extract (0.4 mg/ml protein concentration) and non-transfected cell extract (0.4 
mg/ml) were applied in three dots on a Protran nitrocellulose membrane (Schleicher and 
Schuell, Dassel, Germany). Following blocking in Odyssey blocking buffer (OBB; LiCor 
Westburg, Leusden, The Netherlands) diluted in PBS (1:1) (OBB/PBS), membrane strips 
were separately incubated with rabbit anti-ErbB2-antibody or anti-ErbB4 antibody (positive 
controls), diluted 1:1000 or 1:1500 respectively in OBB/PBS containing 0.5% goat serum 
(GS) (i.e. OBB/PBS/GS), with OBB/PBS/GS (negative control), with patient serum diluted 
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washed three times with PBS 0.1% Tween (Merck), and incubated with IRDye 800 goat 
anti-rabbit IgG (Rockland Immunochemicals), diluted 1:3700 in OBB/PBS/GS, or with 
IRDye 800 goat anti-human IgG (Rockland Immunochemicals), diluted 1:10000. Following 
the washing steps, strips were scanned with the Odyssey scanner (LiCor Westburg) at 800 
nm. Finally, ImageJ software (http://rsb.info.nih.gov/ij/) was used to quantify the integrated 
intensities of the dots. The mean integrated intensity of the background was subtracted. To 
correct for the non-specific binding of antibodies to other proteins than ErbB2 or ErbB4, 
the ratio was calculated between mean intensities of dots of transfected cell extract and dots 
of non-transfected cell extract. These ratios were normalised by dividing them by the mean 
of the NHS ratios. The mean of NHS plus two and three times standard deviation was used 
as cut off value.
statistical analysis
SPSS Software 17.0 was used to perform statistical analyses. Comparison between non-
normally distributed values was performed using the non-parametric Mann-Whitney test. A 
two-sided probability value <0.05 was considered statistically significant.
results
Results of the anti-ErbB antibody measurement by FACS are summarised in Figure 6.1. The 
median MFI of SNMG patients was not significantly higher than that of healthy controls, 
for none of the three cell lines tested. In addition, no individual value of an SNMG patient 
or a healthy control exceeded the cut off value, calculated as the mean plus three times SD 
of the corresponding NHS group (data not shown). These results show that there are no 












































Figure 6.1 Detection of anti-ErbB2/3/4 antibodies by FaCs 
Sera from 42 SNMG patients (SNMG) were screened for anti-ErbB-IgG by flow cytometry. 32D13 cells (expressing 
ErbB1+3); 32D23 cells (expressing ErbB2+3); and 32D24 cells (expressing ErbB2+B4) were incubated with 
serum from patients (solid circles) or normal human serum (NHS) (empty circles). Values are normalised with 
the mean MFI of the corresponding NHS group. Horizontal full lines represent the median MFI per group. The 
Mann-Whitney test did not show a significant increase in median MFI in SNMG patients compared to NHS.
Results of the dot blotting analysis are shown in Figure 6.2. The high transfection efficiency 
of HEK cells with ErbB2 and ErbB4 cDNA was verified by Western blotting (Figure 6.2A). 
Low amounts of ErbB2 receptors were also endogenously present in non-transfected HEK 
cells, whereas ErbB4 receptors were undetectable in non-transfected HEK cells. Figure 
6.2B shows representative dot blots, where non-transfected and transfected HEK cell 
extracts were incubated with SNMG patient serum (Figure 6.2B, row 1), normal human 
serum (Figure 6.2B, row 2), monoclonal anti-ErbB2 antibody (Figure 6.2B, row 3) and 
monoclonal anti-ErbB4 antibody (Figure 6.2B, row 4). To correct for unspecific antibody 
binding to endogenous HEK proteins, the mean integrated intensity of transfected cells 
were divided by the mean integrated intensity of non-transfected cells for each sample. The 
results are summarised in Figure 6.2C. The median fluorescence ratio in SNMG patients 
was significantly lower than that of both positive controls (monoclonal anti-ErbB2 antibody 
(p<0.001) and monoclonal anti-ErbB4 antibody (p<0.001)), but did not differ from the 
median ratio of healthy individuals. In addition to comparing median values of the ratio of 
the different groups, no individual ratio of an SNMG patient or a healthy person exceeded 
the cut off value.
To study the possibility that the negative results were due to low sensitivity of the 
techniques, we validated the sensitivity of the dot blotting protocol (Figure 6.2D). Anti-
AChR antibodies were measured in AChR-MG patients, of whom the anti-AChR antibody 
titre had been determined by RIA before. Anti-AChR antibodies were detectable using the 
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Figure 6.2 Detection of anti-ErbB2/4 antibodies by dot blotting analysis
A) Expression of ErbB2 and ErbB4 in non-transfected (non) and transfected (ErbB2/ErbB4) HEK 293 cells, 
measured by Western blotting. B) Representative dot blots spotted with non-transfected and transfected HEK 
293 cell extracts were incubated with SNMG patient serum (SNMG), normal human serum (NHS), anti-ErbB2 
positive control antibody or anti-ErbB4 positive control antibody. C) Dot blot results of anti-ErbB antibody 
measurement in SNMG patients. Each dot corresponds to the ratio between the mean intensity of triplicate 
measurements of transfected HEK cells and the mean intensity of the non-transfected HEK cells. Horizontal full 
lines represent the median value of the ratio per group, dashed lines show cut off value calculated as the mean of 
NHS plus two and three times the standard deviation. D) Dot blot results of anti-AChR antibody measurement 
in AChR-MG patients. Horizontal full lines represent the median ratio per group, dashed lines show cut off value 
calculated as the mean of NHS plus two and three times standard deviation. The p-values were obtained by the 











































Various studies have identified ErbB receptors, which are present at the NMJ, as potential 
candidates for the autoimmune target in SNMG patients, particularly since myasthenic 
symptoms have been described in ErbB mutant mice. 141-145 The antibody tests for ErbB in 
the sera of the 42 SNMG patients were all negative. This strongly suggests that ErbB does 
not have a role as autoantigen in MG.
The present negative finding could be explained if the sensitivity of our assays for anti-
ErbB would have been too low. However, we successfully used an analogue FACS analysis 
to demonstrate the presence of anti-MuSK antibodies, which confirms the sensitivity of the 
technique (data not shown). The dot blot assay was not able to detect anti-AChR antibodies 
in all the AChR-MG patients, and thus might be too insensitive for detection of low anti-
ErbB antibody titres. A second possibility is that the autoantibodies would only be able to 
bind to ErbB proteins when clustered together in the NMJ, as shown earlier for a subset of 
anti-AChR antibodies. 44 A third, more remote, possibility is that patients with a low titre of 
putative antibodies might bind to the ErbB antigens with very high affinity, thereby leaving 
the blood serum depleted of free antibody. 
If, on the contrary, anti-ErbB antibody would have been present in patients it is questionable 
that they would actually have caused MG-like symptoms. ErbB2 gene amplification and 
protein overexpression are known to be critical for the development of malignancies such as 
breast cancer. For more than ten years, such patients are frequently treated with trastuzumab 
(Herceptin), a humanised IgG1 monoclonal antibody directed against ErbB2. 147-149 Distinct 
side effects can occur during treatment with trastuzumab but, as far as we know, myasthenic 
muscle weakness in patients undergoing this therapy has not been reported, arguing against 
a possible myasthenic effect of anti-ErbB2 antibodies. No reports specifically analysed these 
patients for myasthenic syndromes, leaving the possibility that milder forms of the disease 
might have been missed in these patients.
In conclusion, we could not detect anti-ErbB antibodies in sera of SNMG patients, and 
therefore further research is needed to identify unknown autoantigens. Interestingly, the 
thymic transcriptome of SNMG patients is characterised by a down-regulation of several 
genes involved in synaptic transmission, including neurotransmitter receptors. 150,151 These 
genes could potentially correspond to autoimmune targets, and would be worthwhile to 
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Introduction
Some patients with myasthenia gravis (MG) have autoantibodies to muscle-specific kinase 
(MuSK) instead of the acetylcholine receptor (AChR). Anti-AChR antibodies may be 
transferred across the placenta causing a self-limiting neonatal myasthenic syndrome. We 
describe an infant with a similar disorder whose mother had MuSK MG.
Case report
In September 1994, the mother noticed unilateral ptosis and a feeling of generalised fatigue 
at age 13. Over the next months, she developed severe oculobulbar weakness, dyspnoea and 
weakness of the neck. Symptoms were fluctuating and unresponsive to acetylcholinesterase 
inhibitors. No antibodies to the AChR were found. In 1995, a normal thymus was removed. 
High doses of prednisone had little effect. In 1997, plasmapheresis induced a partial remission 
and this became her regular therapy for several years. In 2004 anti-MuSK antibodies were 
found. She had two first trimester miscarriages while using pyridostigmine and prednisone 
in September and December 2004. In May 2005, she became pregnant using only prednisone 
20 mg on alternating days. This pregnancy was uneventful without large fluctuations of her 
myasthenic symptoms.
In February 2006, at 38+1 week of gestation, she unaidedly delivered a boy in head position. 
Apgar score was 10 after 1 and 5 minutes. Birth weight was 3190 gram (P25). Physical 
examination was unremarkable. After 8 hours, however, drinking became difficult. After 16 
hours, he showed mild generalised hypotonia with diminished facial expression and a weak 
cry. Thirty-two hours after birth, examination showed paucity of general movements, a tent-
shaped mouth and chest retractions. After 10 minutes of examination, weakness increased, 
leading to an immobile frog position (Figure 7.1). Tube feeding was initiated. Intramuscular 
neostigmine gave a temporary improvement of symptoms and oral pyridostimine 0.2 mg 
every 3 hours was started. On day 4, the amount of tube feeding could gradually be decreased. 
Quantities of spontaneously ingested bottle feedings increased from 5 mL on the 4th to 35 
mL on the 8th and to 75 mL on the 13th day. On day 11, examination showed only a mild head 
lag. On day 15, he was discharged, spontaneously drinking his bottles of 7 times 80 mL. 











































Figure 7.1 Neonatal myasthenic weakness on day 3 (top) and remission on day 6 (bottom)
On day 3 the infant shows severe muscle weakness lacking the power to overcome gravity. On day 6, normalisation 
of muscle strength was observed. Parental consent was obtained for publication. 
Maternal and neonatal anti-MuSK specific IgG1 and IgG4 levels were measured by ELISA, 
93 using monoclonal antibodies anti-Human IgG subclasses (IgG1, MH 161-1, Sanquin, 
Amsterdam, The Netherlands, and IgG4, NI315, Nordic, Tilburg, The Netherlands) and 
alkaline phosphatase (AP) labelled Rabbit anti-Mouse Ig (1:750, Dakopatts, Glostrup, 
Denmark). Total IgG anti-MuSK titres were measured using AP labelled Goat anti-Human 
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IgG in pooled sera from MuSK MG patients containing predominantly one anti-MuSK 
specific IgG subclass yielded a factor enabling direct comparison of IgG1 and IgG4 anti-











































































Figure 7.2 Course of maternal (a) and neonatal (B) titres of anti-Musk specific IgG antibodies 
Titres are expressed as arbitrary units per mL compared to an internal standard. The time scale is related to the day 
of conception (A) and the day of birth (B). 











































This case report shows that transient neonatal myasthenia gravis (NMG) is possible through 
cross placental transport of maternal anti-MuSK antibodies. The pathogenicity of the 
antibodies, that are mainly IgG4 in the patients presented here, is supported by the paralleled 
course of neonatal titres and clinical symptoms. NMG without anti-AChR antibodies has 
been described before the role of MuSK in seronegative MG became known. 50 In retrospect, 
anti-MuSK antibodies may have been involved in some of these patients. In AChR MG, 
10 to 15% of the infants develop NMG although autoantibodies are transferred to nearly 
all infants. 152 Giving birth to an infant with NMG seems to enhance the risk of NMG 
in following newborns. 153 There are contrasting data whether the maternal anti-AChR 
antibody titre is predictive for the occurrence of NMG. Both healthy infants from mothers 
with high titres and affected ones from mothers with low titres have been described. 154,155 
Active transport of IgG across the placenta favours IgG1 over IgG4, IgG3 and IgG2 and 
takes place from early in the second trimester. 156 The risk of NMG in IgG4 mediated MuSK 
MG could therefore be lower than in IgG1 mediated AChR MG. The delay between delivery 
and onset of symptoms is remarkable. Most probably, neuromuscular synapses have been 
exposed to maternal anti-MuSK antibodies in utero but the infant had an excellent start and 
fetal development was normal. In animals, extensive remodelling of synapses occurs in the 
weeks after birth and MuSK might play an essential role in this process. In view of the short 
symptom free period, one could also postulate the existence of a short lasting mechanism 
optimizing the first essential muscle contractions of the neonate, like an abundance of 
presynaptic acetylcholine or decreased acetylcholinesterase activity, counteracting the 
myasthenic effect of the antibodies. It should be noted that two earlier pregnancies ended in 
spontaneous abortions with unknown cause. Although these occurred in the first trimester, a 
pathogenic effect of anti-MuSK antibodies in utero cannot be excluded. In pregnant mothers 
with MuSK MG, fetal and neonatal development of the infants should be carefully observed.
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Autoantibodies to muscle-specific kinase (MuSK) can cause myasthenia gravis (MG). The 
pathophysiological mechanism remains unknown. We report in vitro electrophysiological 
and histological studies of the neuromuscular junction in a MuSK MG patient. Low levels of 
presynaptic acetylcholine release and small miniature endplate potentials were found. This 
combination of pre- and postsynaptic abnormalities was supported by histology, revealing 
partially denervated postsynaptic areas, and some degeneration of postsynaptic folds. Results 








































Pre- and postsynaptic neuromuscular junction abnormalities in MuSK myasthenia
85
Introduction
Autoimmunity against the neuromuscular junction leads to muscle weakness in myasthenia 
gravis (MG). Although the majority of patients are seropositive for autoantibodies against the 
postsynaptic acetylcholine receptor (AChR), a minority (<6%) have autoantibodies against 
muscle-specific kinase (MuSK). 54,157 MuSK is a transmembrane tyrosine kinase localised at 
the postsynaptic specialisation of the muscle cell membrane. 65,158 In conjunction with the 
proteins LRP4 73,74 and Tid1, 79 it is involved in the development and maintenance of the 
neuromuscular junction, in particular the clustering of AChRs in the postsynaptic membrane 
through tyrosine phosphorylation, and in the localisation of acetylcholinesterase (AChE) in 
the basal lamina of the synaptic cleft through interaction with its anchoring protein ColQ. 65, 
80 Although the molecular mechanism by which MuSK/LRP4/Tid1 regulate neuromuscular 
junction formation and maintenance has become increasingly clear, 159,160 the pathogenic 
role of anti-MuSK antibodies and the pathophysiological mechanisms by which they may 
cause muscle weakness in MuSK MG are less well understood. The high disease specificity 
of anti-MuSK antibodies, the correlation of their titre with muscle weakness severity, 161 and 
the experimental demonstration in myotubes that these antibodies are capable of reducing 
MuSK-dependent AChR clustering, 54,158 all suggest a pathogenic role. However, no clear 
histological abnormalities consistent with a disturbance of neuromuscular synaptic function 
have been found in biopsies of affected muscles. In particular, a reduction of AChR density 
was not found in morphological studies, in contrast to positive control tissue from AChR 
MG patients. 125,126 Despite these findings, a reduction in the amplitude of miniature 
endplate potentials (MEPPs) was observed in the only MuSK MG biopsy to date in which 
neuromuscular synaptic function was studied with microelectrode methods. 126 MEPPs are 
the unitary postsynaptic responses resulting from spontaneous presynaptic release of single 
acetylcholine (ACh) quanta and their amplitude is largely determined by the density of 
functional AChRs. MEPP amplitude reduction is an established electrophysiological 
hallmark of neuromuscular junctions of AChR MG patients. 162 In view of the apparent 
inconsistency between electrophysiological and morphological observations at biopsied 
MuSK MG neuromuscular junctions and the very limited data reported so far, it is important 
to study function and morphology in additional MuSK MG patients. In this study we describe 
in vitro electrophysiological and histological aberrations of the neuromuscular junction in a 












































Parasternal intercostal muscle tissue was obtained under local anaesthesia using lidocain as 
part of a study of seronegative MG performed at the University Medical Center of Utrecht 
in 1994 and 1995. Approval from the local medical ethics committee and informed consent 
from the patient were obtained. The histological examination took place at the same hospital. 
Immediately after obtaining the biopsied material, part of the biopsy (a few centimetres long) 
was transported in 250 ml of pre-oxygenated Ringer’s medium to the Leiden University 
Medical Center for in vitro electrophysiology studies. 
Endplate electrophysiology
The in vitro electrophysiology studies were performed as described previously. 162 In 
brief, muscle fibers in Ringer’s medium containing 2 mM Ca2+ and 1 mM Mg2+ at 26-
28°C were impaled with a glass microelectrode, connected to standard electrophysiological 
and digitising equipment. In the MuSK MG biopsy, synaptic signals were recorded from 
a sample of 28 endplates. At each endplate, 4-26 MEPPs were recorded, from which the 
mean endplate value was calculated. At each of the 28 studied endplates, 28-42 endplate 
potentials (EPPs) were recorded during 0.3-Hz electrical stimulations of an intramuscular 
nerve branch through a suction stimulation electrode, after allowing for some depolarisation 
to prevent muscle fiber action potentials (at resting membrane potentials of around -65 
and more positive, EPPs at most human muscle fibers no longer trigger an action potential 
162, presumably due to Na+ channel inactivation). The mean resting membrane potential 
during EPP recordings was -67.2 mV. At each endplate a mean 0.3-Hz EPP amplitude 
was calculated from the amplitudes of the recorded EPPs. Whenever possible, EPPs were 
also recorded at 3- and 30-Hz nerve stimulation. Mean MEPP and EPP amplitudes at each 
endplate were normalised to a standard resting membrane potential of -75 mV and EPPs 
were corrected for nonlinear summation. The quantal content, which is the number of ACh 
quanta released per nerve stimulus, was calculated directly by dividing the normalised and 
corrected mean 0.3-Hz EPP amplitude by the normalised mean MEPP amplitude at each 
endplate. From the mean endplate values of each electrophysiological parameter at the 28 
sampled endplates, an overall biopsy mean was calculated. Control data were obtained from 
biopsies of 4 non-neurological-diseased subjects (referred to as “controls”) and 6 patients with 
AChR MG, 162 supplemented by the unpublished results of 17 more AChR MG patients and 
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Endplate histology
Part of the biopsy specimen was pinned out to prevent shrinkage and fixed in a periodate-
lysine-paraformaldehyde solution. For electron microscopy, part of this material was refixed 
in 2% glutaraldehyde solution, postfixed in 1% osmium tetroxide solution, dehydrated 
and embedded in Epon 812. Endplate-containing regions were located in semithin sections 
stained with toluidine blue. Ultrathin sections from selected regions were contrasted with 
uranyl acetate followed by lead citrate and viewed using an electron microscope (1200 EX. 
JEOL Ltd., Tokyo, Japan). Another part of the specimen was freshly frozen with isopentane 
cooled in liquid nitrogen. Longitudinal 50-µm-thick cryostat sections were stained with a 
silver-choline esterase method for intramuscular nerve fibers and endplates. 163
results
The patient
In 1994, a 29-year-old woman experienced fluctuating ptosis and diplopia. Symptoms 
improved upon administering neostigmine. Oral pyridostigmine was unsuccessful, causing 
only gastrointestinal side effects and muscle trembling. Anti-AChR antibodies were negative. 
Two months later, she experienced progressive dysphagia, dysarthria and weight loss. She 
became dyspnoeic after exercise and had to support her head when doing the housekeeping 
and her jaw when chewing. Neurological examination also revealed mild proximal weakness 
of her arms and legs. Anti-AChR antibodies were absent again. Tube feeding was initiated. 
Spirometry showed a reduced vital capacity (71% of predicted) and a very low maximal 
inspiratory pressure (MIP, 21% of predicted). No compound muscle action potential 
decrement was found upon repetitive stimulation of the ulnar, facial and accessory nerve. 
Stimulated single-fiber electromyography of the orbicularis oculi muscles revealed increased 
jitter and blocking. Neostigmine led to slight improvement of the MIP (35% of predicted), 
but also to generalised fasciculations and muscle cramps. Nine months after onset, an 
intercostal muscle biopsy was performed. She had then been off all medication for 3 months. 
After the biopsy, prednisone treatment resulted in marked clinical improvement. In 2002, a 
relapse occurred with neck extensor weakness, diplopia, and mildly impaired swallowing and 
chewing. At this point, anti-MuSK antibodies were found that could also be demonstrated in 
stored serum from 1994. No antibodies to the AChR or voltage-gated calcium channels were 
found. To exclude a genetic cause, the MuSK gene was sequenced, revealing three known 
single-nucleotide polymorphisms (rs1784573, rs2766999 and rs578430), but no mutations 











































The mean MEPP amplitude of the MuSK MG biopsy was 0.33 ± 0.02 mV; that is, 
approximately 50% smaller than the group mean value of the controls (and below the lower 
limit of the range of their individual biopsy mean values), but within the range of biopsy 
mean values from AChR MG patients (Table 8.1). 
Table 8.1 In vitro electrophysiology in Musk MG and controls





















0.33 ± 0.02 2.0 ± 0.02 2.60 ± 0.33 5.78 ± 0.59 2.3 ± 0.11 5.5 ± 0.26 18.8 ± 1.7
































Selcen mean ± SE 0.35 ± 0.02 31 ± 5.8
Controls by Selcen 1.00 ± 0.025 31 ± 1
In vitro electrophysiology data for the MuSK MG patient (biopsy mean was calculated from mean values of 
parameters at n = 28 endplates), AChR MG patients (group mean from biopsy means of n = 23 biopsies, range 
of biopsy means shown in parentheses), and healthy controls (group mean from biopsy means of n = 7 biopsies, 
range of biopsy means shown in parentheses). The last two rows include data published from a MuSK MG patient 
recorded by Selcen et al. 126 Data expressed as mean ± SE (range of biopsy means).
The amplitude of EPPs evoked by 0.3-Hz nerve stimulation was 5.8 ± 0.6 mV; that is, a 
55% reduction compared with the group mean value of controls (Figure 8.1A). The mean 
MEPP frequency was rather low (2.6 ± 0.33 min-1), but still fell within the ranges of AChR 
MG patients and controls. The EPP rise time was slightly smaller than the lower limit of 
the control range, but fell within the AChR MG range. The EPP decay time constant was 
in the range of AChR MG and controls. Mean quantal content was 18.8 ± 1.7; that is, 34% 
lower than the group mean of the controls, 68% lower than the group mean of AChR MG 
biopsies, and clearly below the lower limits of the ranges of the individual biopsy mean 
values of both groups. Upon repetitive 3-Hz nerve stimulation at normal resting membrane 
potentials (about -80 mV), some endplates showed intermittent subthreshold EPPs and 
muscle fiber action potentials triggered by suprathreshold EPPs, as well as delayed action 
potentials triggered by just-above-threshold EPPs (Figure 8.1B). High-rate stimulation 
(30 Hz) at normal resting membrane potential resulted in an increasing occurrence of 
subthreshold EPPs during the stimulation (Figure 8.1C). The 30-Hz EPP recordings at 
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muscle fiber action potentials) showed that the amplitude of the EPP declined during the 
stimulus train to 54 ± 3.6% (n = 28 endplates) of its initial value (Figure 8.1D), which is 
close to the control group mean value (60 ± 4.5%; n = 4 biopsies), but less pronounced than 
the EPP decline level of AChR MG patients (group mean 42 ± 1.4%; n = 23 biopsies), 
although being just within its range of individual biopsy mean values (29-55%). 
Figure 8.1 In vitro electrophysiology in Musk MG
Electrophysiological signals recorded in vitro at neuromuscular synapses of the MuSK MG patient. For clarity, 
stimulus artifacts have been removed. (A) Representative examples of low-rate (0.3 Hz) evoked EPPs and 
spontaneous MEPPs. (B) Five superimposed example traces of responses recorded in the MuSK MG biopsy during 
3-Hz stimulation. Two bare, apparently subthreshold, EPPs are shown and three muscle fiber action potentials, 
apparently triggered by suprathreshold EPPs, with variable delay relative to the moment of stimulation (black 
triangle). (C) Only the first few evoked EPPs trigger a muscle fiber action potential during high-rate (30 Hz) nerve 
stimulation (indicated by black dots). (D) Example trace of the rundown of EPPs at an endplate during 30-Hz 
stimulation.
Histology
Four endplates were available for analysis. One showed a postsynaptic area that was partially 
denuded of nerve terminal area and degenerated secondary postsynaptic folds (Figure 
8.2A). Two other endplates had preserved postsynaptic areas, but were not covered by a 
nerve terminal (Figure 8.2B), although nearby one of these areas a preterminal nerve ending 
could be seen, surrounded by a Schwann cell, imposing as a nerve sprout. Z-disk streaming 
indicated myofibrillar degeneration (Figure 8.2C). One endplate appeared normal. Light 










































Figure 8.2 Histology in Musk MG
Histological studies of the intercostal muscle biopsy. (A) Electron micrograph of a small profile of a nerve terminal 
(centre left) next to an area with degenerating postsynaptic folds. A Schwann-cell (upper right) contains abundant 
lipofuscin. (B) A nerve terminal (right) adjacent to a denuded area with conserved secondary clefts. Terminals 
contain translucent areas, sometimes with lipid remnants. (C) Z-disk streaming compatible with myofibrillar 
degeneration, which is also seen in the lower left corner of A. Bars in A, B and C = 1µm. (D) Light micrograph of 
silver-choline esterase staining for nerve fibers and endplates showing increased branching of intramuscular nerve 
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Discussion
The course of symptoms, with spontaneous fluctuations and a response to immunosuppressive 
therapy, is consistent with that of an acquired autoimmune disorder of neuromuscular 
transmission. This could be confirmed by single-fiber electromyography in vivo, revealing 
an increased jitter and blocking, and by the presence of anti-MuSK antibodies in serum. 
Nine months after onset of symptoms, the biopsy was taken from a clinically affected muscle, 
as judged from the respiratory symptoms and the low spirometry values. At that time, no 
immunosuppressive therapy had been given. The patient had also not been treated with 
acetylcholinesterase inhibitors in the prior months. 
In vitro electrophysiology showed small MEPPs of about half the control size. This is 
compatible with a postsynaptic defect, and has been unambiguously demonstrated at 
biopsied neuromuscular junctions of AChR MG patients. 162,164,165 Reduced MEPPs were 
found in another electrophysiological study of intercostal muscle endplates of a MuSK MG 
patient, 126 and in a preliminary animal study using active immunisation of mice with the 
extracellular domain of human MuSK. 157 Finally, passive immunisation of mice using serum 
obtained from anti-AChR-antibody-negative MG patients who later proved to be positive 
for anti-MuSK antibody, also led to a reduction of MEPP amplitude. 51,157 Thus, MEPP 
amplitude reduction seems to emerge as a general MuSK MG feature. 
In another active immunisation study rabbits were immunised with an extracellular 
MuSK portion. Muscle weakness clearly developed and AChR density, as determined with 
fluorescence labelling, was greatly reduced. 166 However, such a reduction was not found in 
human morphological studies, 125,126 or in the passive transfer study of mice, as determined 
by radiolabelling. 51 This is a puzzling finding and suggests an effect of antibody binding to 
MuSK on AChR function. 
Importantly, whereas in AChR MG an increase in quantal content can be observed as a 
compensatory presynaptic mechanism resulting from retrograde signalling from muscle fiber 
to nerve terminal, 162,165 the biopsy mean quantal content at the endplates of our study patient 
was 68% below that of the group mean of AChR MG patients, well below the lower limit of 
the range of biopsy means within this group, and even lower than in controls. In the MuSK 
MG patient described by Selcen et al., no reduced quantal content was found. 126 The quantal 
content in that study was calculated with the “variance method” (i.e., from fluctuations 
of EPP amplitudes in preparations that were treated by d-tubocurarine to lower EPPs to 
subthreshold amplitude), instead of with the “direct method” without pharmacological 
manipulation, as applied here. The variance method is known to yield overestimated quantal 
content values, 162,167 and thus the value calculated by Selcen et al. may actually have been 
somewhat lower. Another important difference between the Selcen et al. study and our study 










































of relatively stable clinical symptoms, and in the presence of muscular atrophy, unlike the 
present case presented. In their accompanying morphological analyses, the presynaptic and 
postsynaptic neuromuscular junction ultrastructure seemed preserved. 
A presynaptic defect might in theory result from a direct action of anti-MuSK antibodies on 
the presynaptic nerve terminal. However, neuronal presence of MuSK is unlikely, 61 although 
it cannot be completely excluded. 168 It is more likely that the autoimmune attack on 
MuSK in the postsynaptic membrane interferes, either directly or indirectly, with synaptic 
homeostatic and stabilisation pathways, with ensuing disturbance of retrograde signalling 
causing the presynaptic alterations. The observed pre- and postsynaptic defects at endplates 
in the MuSK MG biopsy led to failure of the neuromuscular transmission as indicated by 
small EPPs that became subthreshold, especially at high-rate stimulation of the motor nerve. 
The histological data accompanying our in vitro electrophysiological analyses must be 
regarded as qualitative and do not allow firm conclusions, in view of the large variability 
between endplates and the low number of observations we were able to make, due to the 
limited material. However, the observation of endplates (partially) lacking nerve terminals in 
combination with degeneration of postsynaptic folds and myofibrils supports the combination 
of pre-and postsynaptic abnormalities found in the microelectrode studies. Reduced MEPP 
amplitudes and quantal content have also been described in amyotrophic lateral sclerosis. 169 
In patients with this disorder, a dysfunction of the neuromuscular transmission can be found 
in vivo, and has been attributed to a combined effect of nerve degeneration and regeneration, 
with a small size of nerve terminals, and a conduction block in immature axons. Histological 
studies show (partially) denuded postsynaptic areas with a relatively intact structure of the 
folds, similar to some of the junctions shown herein. 170 
Disturbances in the apposition between pre- and postsynaptic neuromuscular junction 
structures have been demonstrated in mice after passive immunisation with patient anti-
MuSK IgG. 171 These mice showed a myasthenic phenotype, substantiated by a decreased 
density of AChRs in fluorescence-labelling studies and a decrement of compound muscle 
action potentials in repetitive nerve stimulation electromyography. Unfortunately, no in 
vitro electrophysiological analysis was performed at the neuromuscular junctions. 
In conclusion, our electrophysiological and histological data show not only postsynaptic defects 
at the neuromuscular junction of a MuSK MG patient, but also demonstrate presynaptic 
disturbances. It is highly likely that these neuromuscular synaptic deficits are caused by the 
circulating anti-MuSK antibodies and underlie the muscle weakness of the patient. Anti-
MuSK antibodies may reduce the stability of the muscle-nerve contact, leading to a process 
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summary
Muscle-specific kinase (MuSK) antibodies were first described in 2001 by Hoch et al. 54 
In this first cohort of selected patients with generalised myasthenia gravis (MG) without 
antibodies to the acetylcholinereceptor (AChR), 70% tested positive for these new anti-
MuSK antibodies. In the Netherlands, we studied the epidemiology of generalised MG 
subtypes on a regional and national level. We used an area defined by postal codes in the 
Netherlands and patient registries in all hospitals within this region (Chapter 2). MuSK 
MG proved to be a rare disease with an incidence of 0.17 per million person-years, between 
January 1st 1990 and January 1st 2004. On January 1st 2004, the prevalence was 2.8 per 
million inhabitants. 
We then conducted a nationwide study to include all traceable patients with generalised MG 
without antibodies to the AChR. This study yielded similar results, showing an incidence 
of MuSK MG of 0.10 per million per year and a prevalence of 1.9 per million inhabitants. 
Antibodies to the AChR were absent in 14.5% of all patients with generalised MG, of 
whom 22% were MuSK antibody positive. Thus, in the Netherlands approximately 3% of 
all generalised MG patients will have antibodies to MuSK. MuSK MG was characterised by 
a female predominance. The onset of symptoms in MuSK MG varied widely between 2 and 
74.6 years. 
In the clinical study (Chapter 3), we examined the distribution of weakness in generalised 
MG subtypes in more detail. We included the first 25 patients diagnosed with MuSK MG 
during the epidemiological study, and compared them to 50 randomly selected AChR MG 
controls matched for age at onset and sex. The first occurrence of symptoms in a period 
of 5 years after onset of the first MG symptom was investigated retrospectively based on 
a standardised history taking that was applied by a single investigator, and information 
from patients’ charts. The same approach was used for all 41 patients with seronegative MG 
(SNMG). The first symptoms did not discriminate between the various MG subtypes. During 
the course of the study, a new cell-based technique became available, using recombinant 
MuSK or AChR transfected human embryonic kidney cells to test for autoantibodies to 
clustered or overexpressed antigens. Within the group of 41 SNMG patients defined by 
standard radioimmunoassay (RIA), this sensitive technique identified a further 10 patients 
with autoantibodies to AChR and another 10 who tested positive for MuSK autoantibodies. 
In the remaining 21 patients, now newly defined as seronegative, weakness was characterised 
by mild proximal limb-girdle distribution with frequent involvement of the extraocular 
muscles, with ptosis occurring more often than diplopia. 
In patients with MuSK MG, weakness predominantly affected bulbar and neck muscles 
during the course of the disease. Among the symptoms pointing at bulbar muscle weakness, 










































By contrast, chewing was relatively spared. Dyspnoea was reported more often by MuSK MG 
patients, and occasionally even as the first symptom. Respiratory support was needed within 
five years after the onset of symptoms in 28% of MuSK MG patients, as compared to only 
10% of AChR MG patients. MuSK MG patients also showed an increased sensitivity of 
muscle fibers to acetylcholinesterase inhibitors leading to muscle twitching and cramps. The 
phenotype of patients with antibodies to overexpressed MuSK in the cell-based assay only 
was similar to that of patients who already tested positive for anti-MuSK antibodies in the 
conventional radioimmunoassay (RIA). 
Among patients with MuSK MG, 22% had a second autoimmune disease and 35% had a 
first-degree relative with such a disorder, mainly affecting the thyroid gland. One of the 
best known genetic factors predisposing for autoimmune diseases is the HLA genotype. 
AChR MG without thymoma and the Lambert-Eaton myasthenic syndrome without small-
cell lung cancer are both linked to the HLA-B8-DR3 haplotype. No tumour is associated 
with MuSK MG, so we hypothesised a similar association with HLA-B8-DR3 in this disease. 
However, in Chapter 4 we presented evidence that MuSK MG is strongly associated with 
HLA-DR14-DQ5. The same haplotype has also been linked to pemphigus vulgaris, an 
autoimmune disorder causing blistering of the skin. Interestingly, autoantibodies in both 
pemphigus and MuSK MG are mainly of the IgG4 subclass. 
We studied the relation between clinical disease severity in MuSK MG patients and the titres 
of antigen-specific IgG subclasses (Chapter 5). For this purpose, we developed the Disease 
Severity Score (DSS), a new classification that can be used for retrospective MG studies. The 
score yielded semi-continuous variables that allowed regression analysis using a linear mixed 
effect model. In six patients who had been followed during 2.5 to 13.4 years and from whom 
7 to 12 serum samples had been stored, we found a significant association between antigen-
specific IgG4 titres and DSS on a group level (β coefficient 0.44, p = 0.036). No such 
association was found for IgG1 titres (β coefficient -0.32, p = 0.13). Total antigen-specific 
IgG was weakly associated with DSS. A positive correlation between anti-MuSK specific 
IgG4 and the DSS was found in 5 of the 6 patients. 
In Chapter 6 we studied the presence of autoantibodies to ErbB receptors in patients with 
SNMG. ErbB receptors are transmembrane proteins in the neuromuscular junction and, as 
such, antigens potentially exposed at sites not hidden from the immune system. Animal 
studies had shown a crucial role for ErbB receptors in the development of the neuromuscular 
junction. However, we were unable to detect anti-ErbB antibodies in sera of 42 SNMG 
patients defined by RIA from the original cohort using fluorescence-activated cell sorting 
and dot blotting analysis on transfected human embryonic kidney cells.
Finally, two patients with MuSK MG are described in detail in Chapters 7 and 8. In the 
first case, maternal anti-MuSK antibodies caused a transient myasthenic syndrome in the 
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subclass in both mother and child. Symptoms in the neonate occurred with a slight delay of 
approximately 8 hours and disappeared in 6 days. In the second case report, a combination 
of pre- and postsynaptic defects was found in a 29-year old woman with MuSK MG. In 
vitro electrophysiological studies performed on an intercostal muscle 9 months after onset 
of symptoms revealed low miniature end-plate potentials and low levels of presynaptic 
acetylcholine release. Histology showed partially denervated postsynaptic areas and some 
degeneration of postsynaptic folds. 
Discussion
Defining the exact prevalence of MG subtypes remains challenging. In the course of this 
study, radioimmunoassays became more widely available and the clinical characteristics 
of the MuSK MG subtype became better known. This facilitated the diagnosis of MuSK 
MG, increasing the calculated prevalence of the disease. Referral bias also complicates the 
comparison of epidemiological studies from various countries as is shown by the slightly 
higher proportion of MuSK antibodies in our nationwide study, as compared to regional 
figures (36% versus 22% of generalised AChR Ab- MG). Not all MG patients are referred 
to specialised neuromuscular clinics, especially when weakness is only mild. In Chapter 3 we 
show that this is more often the case in SNMG than in MuSK MG. During this study, newly 
developed cell-based assays became available, identifying patients who tested negative in the 
standard radioimmunoassay, with autoantibodies only to clustered AChR or overexpressed 
MuSK antigens. This technical progress will lead to a higher prevalence of MuSK MG 
at the expense of SNMG and complicates the comparison of studies, both over time and 
geographically. 
The concept of a North-South gradient in the prevalence of MuSK MG originated from 
European and North American studies showing for example a prevalence of 0% in Norway, 
22% in The Netherlands and 40 % in Italy. 157 However, it does not apply for Asian 
populations where 41% in Japan (northern latitude 35°) is higher than 26.7% in Korea 
(northern latitude 37°) and 2.5-4% in China (northern latitudes 32°–34°). 172 The female 
predominance in MuSK MG is consistent in all studied populations. Our observation of 
a relatively high proportion of black MuSK MG patients in the Netherlands has been 
confirmed in two American studies. In a cohort described in North-Carolina, 44% of MuSK 
MG patients were of African-American origin, although the percentage of black people in 
the general population is not mentioned. 110 Among AChR antibody negative MG patients 
in Alabama, MuSK antibodies were found in 50% of those from Afro-American origin. 
Among white AChR antibody negative MG patients, the proportion of MuSK antibodies 










































In the ten years after the first publication of anti-MuSK antibodies, MuSK MG has emerged 
as a rare but distinct disease entity. The differences in clinical course, genetic susceptibility 
and pathogenesis between MuSK MG and AChR MG have been highlighted in this thesis. 
In 2004, the role of MuSK antibodies was still subject of debate because of the absence of 
AChR and MuSK deficiency in a thoroughly studied muscle biopsy of a MuSK MG patient. 
126 However, the case of a mother and child described in Chapter 6 fits Koch’s postulate 
originating from the field of microbiology, and adapted for the use in autoimmunity to 
determine the causality between antibody and disease. Here, the passive transfer of an 
autoimmune factor to a susceptible “host” results in induction of the disease. This has been 
confirmed in other cases of neonatal myasthenic syndromes in MuSK MG. 174-176 Final proof 
was published in 2008 by Cole et al. who showed that IgG derived from MuSK MG patients 
caused a neuromuscular transmission defect in mice with reduced postsynaptic AChR 
staining and a reduced apposition of the nerve terminal and the postsynaptic AChR. 171 The 
combination of pre- and postsynaptic abnormalities in MuSK MG was further substantiated 
by Mori et al., who showed that active immunisation in mice with the rat-MuSK ectodomain 
caused axonal sprouting, with or without nerve terminals and reduced density of AChR 
clusters. 177 Again, in vitro electrophysiology showed reduced MEPP amplitudes and a 
reduced quantal content. MuSK antibodies also impaired acetylcholinesterase function, 
which is consistent with clinical observations in patients of an increased sensitivity to 
acetylcholinesterase inhibitor treatment resulting in muscle cramps and fasciculations.
The crucial role of IgG4 MuSK antibodies described in Chapter 5 was proven recently by 
Klooster et al. in a passive transfer study using purified IgG4 and IgG1-3 fractions from 
MuSK MG patients. 178 In this study, purified IgG4, but not IgG1-3, caused myasthenic 
weakness in mice. In vitro electrophysiology revealed a reduction of postsynaptic acetylcholine 
sensitivity and exaggerated depression of presynaptic acetylcholine release which is similar 
to the human in vitro studies described in Chapter 9. The IgG4 antibody in general has 
interesting properties, i.e. the inability to activate complement and the possibility of Fab 
arm exchange which makes many IgG4 antibodies functionally monovalent. Mori et al. 
showed that these monovalent MuSK Fab arms are sufficient to inhibit agrin-induced AChR 
clustering and MuSK phosphorylation in C2C12 myotubes. 177 
Future perspectives
An IgG4 immune response is thought to be triggered by chronic antigen exposure. 129 
This suggests that a constantly present environmental factor might be responsible for the 
initiation of the immune response. It would be interesting to study similarities between 
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involved in the onset of MuSK MG. It is also possible that the humoral immune response 
to antigen exposure in general is different in MuSK MG patients. This can be investigated 
by studying IgG subclass response to other antigens such as tetanus toxin in MuSK MG 
patients, and compare them to AChR MG and healthy controls. 
The apparent fluctuation in disease severity that has been associated to IgG4 titres should 
be studied in more detail. It is clear in MG that the autoantibody titre is not the most 
important factor to determine the severity of symptoms. Patients can be severely affected 
with very low autoantibody titres or vice versa. 37 Increasing evidence exists that the 
inflammatory properties of IgG depend on the type of glycosylation of the Fc moiety affecting 
the interaction with Fcγ receptors. 179 Fc-glycosylation can change over time and has been 
associated to fluctuation in disease severity in several autoimmune disorders like rheumatoid 
arthritis. 180 Recently, we were able to detect changes in total IgG Fc N-glycosylation in a 
cohort of LEMS and AChR MG patients. 181 It seems worthwhile and feasible to explore 
changes in total IgG glycosylation over time in longitudinal studies such as described in 
Chapter 5. It may be even more interesting to study the glycosylation of antigen-specific 
IgG although this is technically challenging.
The effect of MuSK antibodies on the neuromuscular transmission also needs to be clarified 
in more detail. MuSK is thought to act mainly in synapse development and maintenance, 
processes with a relatively low turnover. On the other hand, patients can respond to plasma 
exchange within one or more days suggesting a quickly reversible dysfunction. 110 This 
suggests that MuSK may also have a role in synaptic signal transmission itself, or that MuSK 
antibodies can block the function of the neuromuscular synapse without causing structural 
damage. 
Recently, treatment with rituximab seemed to be effective in MuSK MG. 182 This monoclonal 
antibody binds to the CD20 antigen. This antigen is expressed on B-cells, but not on 
plasma cells. Currently it is believed that antibody-dependent cell mediated cytotoxicity 
is the major mechanism of action of rituximab induced B-cell depletion. It also leads to 
complement mediated cell lysis and apoptosis of B-cells, and may have a regulatory effect 
on the cell cycle. 183 Further studies should aim to determine whether this expensive but 
well tolerated therapy may even be the first choice in MuSK MG, and has a sustained effect. 
Early and effective treatment may prevent irreversible muscle atrophy later on in the course 
of the disease. Developing a good symptomatic treatment in MuSK MG is also important 
as AChE inhibitors are clearly not useful in MuSK MG. Ephedrine and salbutamol improve 
muscle weakness in the Dok7 congenital myasthenic syndrome. 184,185 Both substances act on 
β2-adrenergic receptors that have two major effects on muscle. The first is anabolic through 
activation of adenylate cyclase, induction of intracellular cyclic AMP, subsequent activation 
of protein kinase A, and the inhibition of proteolytic pathways. The second is through the 










































kinase Akt which then phosphorylates numerous intracellular targets. 186 Considering the 
close interaction between MuSK and Dok7, and the crucial role of phosphorylation in the 
neuromuscular synapse as described in the introduction of this thesis, the salbutamol-induced 
increase in kinase activity may partially compensate for reduced MuSK signalling caused 
by the autoantibodies. Defining a clinical parameter to study the effect of symptomatic 
medication is, however, challenging in a fluctuating and predominantly bulbar disease like 
MuSK MG. 
New antigens involved in SNMG might be discovered in the near future. LRP4 may be a 
target although the pathogenicity of the antibodies described in MG patients until now 
remains to be proven. The same applies for other proteins that play a role in the neuromuscular 
junction and that are (partially) located extracellularly and therefore accessible to antibodies. 
Some are mutated in congenital myasthenic syndromes such as laminin β2 or agrin. 91,187 
Autoantibodies to potassium channels or AChE have been detected in AChR MG, and may 
theoretically also be present in SNMG although their role remains to be clarified. 188,189
One of the enigmas in the field of neuromuscular diseases in general,and no less in that of 
myasthenia gravis, is the distribution of clinical weakness i.e. the different response of various 
muscles to omnipresent autoantibodies or genetic mutations. This also applies for MuSK MG 
with its distinct oculobulbar and axial weakness. It is clear that some striated muscles are 
different from others. Many physiological and immunological aspects have been described. 
Extraocular muscles, often involved in MG, have more tonic contractile characteristics and a 
lower expression of complement inhibitory genes. The ocular motorneurons also have high 
firing frequencies. Such factors probably make their neuromuscular transmission particularly 
vulnerable to autoimmune pathology. 190 Differences of intrinsic MuSK expression in various 
rat muscles have also been reported. 191 Further research identifying the underlying cause 
of the vulnerability of some muscle and the resistance of others will probably benefit from 
technicological progress in the field of genetics, like the availability of cDNA or protein 
arrays. Nonetheless, careful study of the signs and symptoms of patients will be indispensable 












































Myasthenia gravis (MG) is een ziekte die wordt gekenmerkt door in de tijd wisselende 
spierzwakte die op enig moment in het leven begint. In een gedetailleerde publicatie van 
Erb en Goldflam aan het eind van de 19e eeuw beschreven zij dat bij MG het hangen van 
de oogleden (ptosis) en oogbewegingsstoornissen die leiden tot dubbelzien (diplopie) vaak 
de eerste symptomen zijn. Men spreekt dan van oculaire MG. Dit kan gevolgd worden door 
zwakte van bulbaire spieren met moeite bij kauwen, slikken en spreken, en gaat vaak gepaard 
met uitbreiding van de spierzwakte naar nek, armen en benen. Dit wordt gegeneraliseerde 
MG genoemd. Kenmerkend zijn de sterke wisselingen van de spierzwakte en de toename 
daarvan aan het einde van de dag en na inspanning. In 1934 lokaliseerde Walker de oorzaak 
van MG in de spierzenuw overgang (neuromusculaire synaps) door een kortdurend effect 
van een middel dat de afbraak van acetylcholine remt. Acetylcholine wordt door de zenuw 
afgegeven en draagt het signaal over naar de spier door binding aan de postsynaptische 
acetylcholine receptor (AChR). In 1976 toonden Lindstrom et al. antilichamen tegen deze 
AChR aan bij 87% van in totaal 71 patiënten met gegeneraliseerde MG. Deze antilichamen 
worden door het eigen immuunsysteem gemaakt en zijn gericht tegen lichaamseigen 
eiwitten. Myasthenia gravis is daarmee een autoimmuunziekte. De autoantilichamen tegen 
de AChR zijn vooral van de IgG1- en IgG3-subklasse. Dit type antilichamen veroorzaakt de 
transmissiestoornis door beschadiging van de postsynaptische membraan via activering van 
complement, een versnelde afbraak van AChRs en mogelijk ook door het blokkeren van de 
acetylcholine bindingsplaatsen. De autoantilichamen kunnen worden aangetoond met een 
radioimmunoassay. Hierin binden de autoantilichamen aan radioactief gelabelde receptoren 
en vormen zo complexen die neerslaan. De hoeveelheid radioactiviteit wordt gemeten en is 
een maat voor de hoeveelheid antilichamen. Bij ongeveer 10 tot 15% van de patiënten met 
gegeneraliseerde MG konden in het bloed echter op deze manier geen antilichamen tegen 
de AChR worden gevonden. Deze patiënten werden geclassificeerd als seronegatieve MG 
(SNMG). In 2001 werden voor het eerst antilichamen tegen muscle-specific kinase (MuSK) 
beschreven bij 70% van een cohort geselecteerde patiënten met SNMG. Het doel van dit 
proefschrift was de klinische verschijnselen van deze nieuwe ziekte te onderzoeken en het 
onderliggende immunologische mechanisme te verhelderen.
Proefschrift
In hoofdstuk 2 onderzochten we de epidemiologie van de verschillende vormen van 
gegeneraliseerde MG op zowel regionaal als landelijk niveau. Hiervoor definieerden we in 
Nederland een regio op basis van postcode en includeerden MG patiënten van alle ziekenhuizen 










































MG) een zeldzame aandoening was. De incidentie, dat wil zeggen het aantal patiënten dat 
de ziekte krijgt in een bepaalde periode, was 0,17 per miljoen persoonsjaren tussen 1 januari 
1990 en 1 januari 2004. De prevalentie, of met andere woorden, alle patiënten die met de 
ziekte op een bepaald tijdstip in leven zijn, was 2,8 per miljoen inwoners op 1 januari 2004. 
Vervolgens deden we landelijk onderzoek om alle traceerbare patiënten met gegeneraliseerd 
MG zonder antilichamen tegen de AChR te includeren. De resultaten van dit onderzoek 
waren vergelijkbaar met die uit het regionale onderzoek. De incidentie van MuSK MG was 
0,10 per miljoen persoonsjaren. De prevalentie was 1,9 per miljoen inwoners op 1 januari 
2004. Van alle patiënten met gegeneraliseerde MG had 14,5% geen antilichamen tegen 
de AChR. Van deze seronegatieve patiënten had slechts 22% antilichamen tegen MuSK. 
Daarmee heeft ongeveer 3% van alle patiënten met gegeneraliseerde MG antilichamen tegen 
MuSK. Een van de kenmerken van MuSK MG was dat het vaker voorkomt bij vrouwen. De 
leeftijd waarop patiënten de eerste symptomen kregen varieerde sterk tussen 2 en 74 jaar.
In het klinisch onderzoek beschreven in hoofdstuk 3, onderzochten we de verdeling van de 
spierzwakte bij de drie vormen van gegeneraliseerde MG in detail. We includeerden de eerste 
25 patiënten die vanuit het landelijk epidemiologisch onderzoek werden geïdentificeerd met 
MuSK MG en vergeleken hen met 50 patiënten met gegeneraliseerde MG en antilichamen 
tegen de AChR (AChR MG). Deze werden in de verhouding 2:1 willekeurig geselecteerd 
uit databases in Leiden en Groningen, waarbij ze werden gepaard wat betreft geslacht en 
de leeftijd waarop de eerste symptomen van de ziekte waren begonnen. Met behulp van 
gegevens uit de medische status en een hernieuwde anamnese met de patiënt werd het 
moment bepaald waarop symptomen voor het eerst waren opgetreden in de eerste 5 jaar na 
het begin van de ziekte. Dit werd ook gedaan bij patiënten met SNMG. Met behulp van 
alleen het symptoom dat het allereerst optrad kon geen onderscheid gemaakt worden tussen 
de verschillende vormen van MG. Gedurende de duur van dit onderzoek werd ook een andere 
techniek ontwikkeld om antilichamen tegen de AChR of MuSK aan te tonen. Deze techniek 
maakt gebruik van cellen die kunstmatig AChR of MuSK aan hun celoppervlakte tot 
expressie brengen. Na toevoegen van serum van patiënten kan door een kleuring het binden 
van antilichamen aan deze cellen worden aangetoond. Binnen de groep van 41 patiënten 
die volgens de gebruikelijke methode met een radioimmunoassay waren gediagnosticeerd 
als SNMG, bleken met deze nieuwe techniek bij 10 patiënten toch antilichamen tegen de 
AChR aantoonbaar. Nog eens 10 andere patiënten hadden antilichamen tegen MuSK. Bij de 
resterende 21 patiënten met SNMG bleek de zwakte voornamelijk in de proximale bekken- 
en schoudergordel spieren te zitten. Ook waren de externe oogspieren vaak betrokken 
wat meestal leidde tot ptosis (hangen van de oogleden) en in mindere mate tot diplopie 
(dubbelzien).
Patiënten met MuSK MG hadden met name zwakte van bulbaire spieren en nekspieren. Van 










































spraak) en dysphagie (moeite met slikken) het vaakst genoemd, gevolgd door gelaatszwakte. 
Het kauwen was daarentegen relatief gespaard. Benauwdheid werd vaker als symptoom 
genoemd door patiënten met MuSK MG en bij een enkeling zelfs als het eerste symptoom 
van de ziekte. Binnen de eerste 5 jaar na het begin van de ziekte kwam 28% van de MuSK 
MG patiënten op de IC terecht voor een periode met kunstmatige beademing in vergelijking 
met maar 10% van de patiënten met AChR MG. Bij patiënten met AChR MG gaf medicatie 
die de afbraak remt van acetylcholine door remming van het enzym acetylcholinesterase 
vaak een verbetering van de spierzwakte. De spieren van patiënten met MuSK MG waren 
daarentegen vaker overgevoelig voor deze medicatie wat bleek uit het spontaan samentrekken 
van spiervezels zonder dat de spierzwakte verbeterde. De verschijnselen van de 10 patiënten 
bij wie de antilichamen tegen MuSK alleen aantoonbaar waren met behulp van de nieuwe 
cel techniek waren identiek aan die van de 25 MuSK MG patiënten bij wie de antilichamen 
met behulp van de gebruikelijke radioimmunoassay gevonden waren. 
In hoofdstuk 4 wordt beschreven dat 22% van de patiënten met MuSK MG een tweede 
autoimmuunziekte heeft en 35% een eerstegraads familielid met een dergelijk aandoening. 
Een van de bekendste genetische factoren die de gevoeligheid voor het krijgen van 
autoimmuunziekten bepaalt zijn de HLA genen. Twee vormen van myasthenie, namelijk die 
met antilichamen tegen de AChR en die met antilichamen tegen een presynaptisch calcium 
kanaal (het Lambert-Eaton myastheen syndroom), zijn geassocieerd met HLA-B8-DR3 
indien de patiënten geen tumor hebben (geen thymoom bij AChR MG of geen kleincellig 
longcarcinoom bij LEMS). Aangezien bij MuSK MG geen tumoren zijn beschreven 
veronderstelden we dat HLA-B8-DR3 ook bij deze patiënten vaker gevonden zou worden. 
Zoals beschreven in hoofdstuk 4 bleek echter dat MuSK MG geassocieerd is met een ander 
type HLA, namelijk HLA-DR14-DQ5. Dit type komt ook vaker voor bij patiënten met 
pemphigus vulgaris. Dit is een autoimmuunziekte van de huid die leidt tot blaarvorming. 
Belangwekkend is dat de autoantilichamen bij zowel pemphigus als MuSK MG van een 
bepaald type zijn, de IgG4 subklasse.
In hoofdstuk 5 wordt de relatie tussen de ernst van de symptomen en de hoeveelheid 
antilichamen tegen MuSK van verschillende IgG subklassen beschreven. We ontwikkelden 
een score systeem dat het mogelijk maakte retrospectief de ernst van de symptomen te 
bepalen. Deze score leverde een variabele op die gebruikt kon worden voor statistische 
analyse met behulp van regressie analyse in een lineair gemengd effect model. We konden 6 
patiënten met MuSK MG includeren die gedurende 2,5 tot 13,4 jaar waren gevolgd en van 
wie er bij ieder tussen de 7 en 12 bloedmonsters waren bewaard. Op groepsniveau vonden 
we een verband tussen de ziekte ernst en de hoogte van de IgG4 antilichamen tegen MuSK, 
maar niet de hoogte van IgG1 antilichamen of van de totale hoeveelheid IgG tegen MuSK. 
Bij analyse van de patiënten afzonderlijk bleek er een positieve relatie tussen de hoogte van 










































In hoofdstuk 6 onderzochten we of er bij patiënten met SNMG antilichamen waren tegen 
een ander eiwit, de ErbB receptor. ErbB receptoren zijn eiwitten die in de spiercelmembraan 
van de neuromusculaire synaps tot expressie komen. Ze kunnen daarom mogelijk door 
het afweersysteem worden gezien en dienen als antigeen voor een autoimmuunziekte. In 
dierexperimenteel onderzoek is ook een belangrijke rol van deze eiwitten bij de aanleg van de 
neuromusculaire synaps beschreven. Met behulp van cellen die ErbB receptoren kunstmatig 
tot expressie brengen en twee technieken om eventueel gebonden antilichamen zichtbaar te 
maken, konden we echter geen antilichamen tegen ErbB receptoren vinden in het bloed van 
42 patiënten met SNMG.
Tenslotte wordt in de hoofdstukken 7 en 8 de ziektegeschiedenis van enkele patiënten 
beschreven. Bij de eerste casus in hoofdstuk 7 veroorzaakten antilichamen tegen MuSK 
die aanwezig zijn in het bloed van de moeder een tijdelijke myasthene spierzwakte bij 
haar pasgeboren kind. Ook deze antilichamen waren vooral van de IgG4 subklasse. De 
verschijnselen bij het kind begonnen ongeveer 8 uur na de geboorte en verdwenen op de 
zesde dag. Een dergelijke overdracht van symptomen door antilichamen is belangrijk omdat 
het één van de bewijzen vormt dat deze antilichamen ook daadwerkelijk ziekmakend zijn. 
De tweede casus in hoofdstuk 8 beschrijft een vrouwelijke patiënt met MuSK MG bij wie 
een spierbiopt met daarin neuromusculaire synapsen is onderzocht. Dit was gedaan in de 
tijd dat antilichamen tegen MuSK nog niet waren ontdekt met het doel de diagnose MG 
te bevestigen. Elektrofysiologisch onderzoek van de spierzenuw overgang liet zien dat de 
signaaloverdracht was verminderd. Deze verstoring bevond zich zowel aan de kant van de 
zenuw (presynaptisch, er werd minder acetylcholine afgegeven) als aan de kant van de spier 
(postsynaptisch, het door de zenuw afgegeven acetylcholine genereerde een te lage elektrische 
potentiaal). Dit is anders dan bij AChR MG waar het probleem postsynaptisch is door een 
tekort aan receptoren. Licht- en elektronenmicroscopisch onderzoek liet zien dat delen van 
de postsynaptische spiermembraan geen tegenoverliggende zenuw meer hadden en dat de 
plooiing van deze spiermembraan was verminderd.
Samenvattend is in dit proefschrift beschreven dan MuSK MG een zeldzame maar duidelijk 
te onderscheiden ziekte is. Zowel de klinische verschijnselen, de genetische aanleg om de 
ziekte te krijgen, het type antilichaam waarmee het immuunsysteem de ziekte veroorzaakt 
en manier waarop de antilichamen de signaaloverdracht in de spierzenuw overgang verstoren, 






















































































AAEM  American Association of Electrodiagnostic Medicine
Ab +/-  antibody positive / negative
ACh  acetylcholine
AChE  acetylcholinesterase
AChEI  acetylcholinesterase inhibitor
AChR  acetylcholine receptor
AChR MG myasthenia gravis with autoantibodies to AChR
ATP  adenosine triphosphate
AU  arbitrary units
CI  confidence interval
CK  creatine kinase
CMAP  compound muscle action potential
ColQ  collagen Q
CV  coefficient of variation
DHPR  dihydropyridine receptor
DSS  disease severity score
EGFP  enhanced green fluorescent protein
EMG  electromyography
EPP  endplate potential
FACS  fluorescence-activated cell sorting
GMG  generalised myasthenia gravis
HEK  human embryonic kidney
HLA  human leukocyte antigen
Ig  immunoglobulin
IV  intravenous
IVIG  intravenous human immunoglobulin
kDa  kilo Dalton
LEMS  Lambert-Eaton myasthenic syndrome
LRP4  low-density lipoprotein receptor-related protein
MASC  myotube associated specificity component
MEPP  miniature endplate potential
MFI  mean fluorescence intensity
MG   myasthenia gravis
MGFA  Myasthenia Gravis Foundation of America
MIP  maximal inspiratory pressure










































MuSK  muscle-specific kinase
MuSK MG myasthenia gravis with autoantibodies to MuSK
NHS  normal human serum
NMJ  neuromuscular junction
OD  optical density
OMG  ocular myasthenia gravis
OR  odds ratio
PBS  phosphate buffered saline
PCR  polymerase chain reaction
PE  plasma exchange
PEI  polyethylenimine
PV  pemphigus vulgaris
RIA  radioimmunoassay
RNA  ribonucleic acid
RNS  repetitive nerve stimulation
RT  room temperature
SFEMG  single-fiber electromyography
SNMG  seronegative MG – MG without autoantibodies to AChR or MuSK
Tid1  tumorous imaginal disc protein
TX  thymectomy
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